

BMJ Open

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006326
Article Type:	Protocol
Date Submitted by the Author:	07-Aug-2014
Complete List of Authors:	Wang, Linpeng; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Wang, Lichen; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Shi, Guangxia; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Zeng, Lin; Peking University Third Hospital, Research Center of Clinical Epidemiology Yang, Yi; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department ZHANG, Tao; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Liu, Hiulin; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Urology, Neurology, Complementary medicine, Rehabilitation medicine
Keywords:	Urinary incontinences < UROLOGY, Neurology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

LinPeng Wang¹, Lichen Wang¹, GuangXia Shi¹, Lin Zeng², Yi Yang¹, Tao Zhang¹, HuiLin Liu^{1*}

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University, Beijing, China

Correspondence to Dr. Hui-Lin Liu*; lhlxwy@aliyun.com

ABSTRACT

Introduction: Ginger-salt-indirect moxibustion is widely applied to treat urge urinary incontinence after stroke, which is a common complication in stroke survivors. Moxa cone moxibustion and moxa box moxibustion are main patterns of ginger-salt-indirect moxibustion. Our previous study had shown that ginger-salt-indirect moxibustion using moxa cones was feasible and effective to treat urination disorders post-stroke. This pilot study aims to assess the feasibility of a research that evaluate the efficacy and safety of ginger-salt-indirect moxibustion for patients with post-stroke urge urinary incontinence.

Methods and analysis: This is a multicenter, prospective, single-blinded, pilot randomized controlled trial. 120 eligible patients with urge urinary incontinence after stroke will be randomly allocated to three groups. Treatment group A (n = 40) will receive moxa cone moxibustion and routine care; treatment group B (n = 40) will receive moxa box moxibustion and routine care; control group (n = 40) will only receive routine care for stroke recovery. The entire moxibustion treatment course will consist of 28 sessions in 4 weeks. Primary outcome measure is increase of mean volume per void at week 4 from the baseline, basing on the data of a 72-hour frequency-volume chart. Secondary outcome measures include mean frequency of urination per day and quality of life assessments measured by completion of Incontinence Quality of Life Questionnaire and Barthel Index. All outcome measures will be assessed before the first moxibustion session, at 4 weeks and 16 weeks after the first moxibustion session. Adverse events in both groups will be recorded to assess safety of moxibustion.

Ethics and dissemination: Research ethics was approved by Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). Written informed consent will be achieved from all participants. Study results will be published in peer-reviewed journals.

Trial Registration number: ISRCTN 44706974.

Strengths and limitations of this study

First pilot study to evaluate the feasibility of a research that assess the efficacy and safety of ginger-salt-indirect moxibustion for UUI after stroke

Multicentre, randomised controlled trial with pragmatic design

Interventions conducted by certified acupuncturists according to the STRICTOM and GCP.

Lack of blinding of acupuncturists and participants due to the nature of moxibustion

INTRODUCTION

Urinary incontinence (UI) is defined as involuntary leakage of urine that causes hygienic or social problems by International Continence Society (ICS)^[1]. Prevalence of UI after stroke varies from 32–79% at admission^[2-4], 25% at hospital discharge and 15% after one year^[4]. As a common type of UI^[5], urge urinary incontinence (UUI) after stroke is characterized by involuntary loss accompanied or preceded by urgency^[1], which arises from acute cerebral accident onset.

Stroke causes deficiency of inhibitory neurons and leads to neurogenic detrusor overactivity^[6]. This seems to be the primary mechanism of UUI after stroke^[1, 7-9]. Detrusor overactivity is characterized by involuntary detrusor contractions during filling and storage phase^[1, 6, 10]. When intra-detrusor pressure generated by abnormal detrusor contractions exceeds sphincter pressure, urinary incontinence occurs^[6]. UI is a strong prognostic indicator for stroke recovery, which is associated with high rates of mortality^[11, 12], disability^[13] and increasing admission to institutional care^[14]. Micturition disorders may result in urinary infection, nephritis, fungal dermatitis^[15], even bedsores. Typical symptoms, including frequent micturition, nocturia and urgency (compelling desire to void which is difficult to defer), could lead to impaired quality of life^[16] and heavy economic burdens^[17, 18].

Initial treatments for UUI after stroke recommended by ICS are behavioral therapy and pharmacotherapy^[1]. Behavioral therapies, including healthy bladder habits and training techniques, aim at changing patients' lifestyle and at teaching patients to control urgency and enhance continence ability^[19]. For habit modification, patients are guided to re-establish a healthy voiding schedule, eliminate bladder irritants from the diet, manage fluid intake and bowel regularity, control weight and give up smoking^[20-26]. Training techniques consist of bladder training, urgency control techniques, pelvic muscle exercises, delayed voiding and multicomponent behavioral training^[19]. Behavioral interventions could be applied in the primary care setting, with or without pharmacotherapy^[27-29]. Among these strategies, behavioral training and bladder training have the strongest evidences for the treatment of UUI^[30-33]. Antimuscarinic drugs can reduce urgency and improve bladder function with the mechanism of controlling detrusor muscle overactivity by inhibiting M2 and M3 muscarinic receptors on bladder^[34-36]. Several meta-analyses have shown that the most widely used antimuscarinic drugs have significant clinical benefits on UUI^[37-40].

1
2
3 Nevertheless, application of antimuscarinic agents is influenced by dosing convenience, drug
4 contraindication and financial consideration^[41]. A recent cochrane systematic review concluded
5 that no rigorously studies designed to manage urinary incontinence after stroke in secondary care
6 had been conducted by far^[42]. Evidences from relevant trials were insufficient to guide clinical
7 practices^[43]. More available therapies and well-designed studies are required to provide further
8 evidences for management of UUI after stroke.
9

10 Moxibustion is a therapy using ignited materials (usually moxa) to heat certain points of skin
11 surface. This technique has been widely used as a treatment for cold syndrome and chronic
12 deficiency diseases^[44] and UUI was regarded as one of common indications^[45]. Despite uncertain
13 modern mechanisms, it is generally identified that action of moxibustion is produced by the
14 meridian system combining with thermal, radiation and pharmacological effects of the materials
15 used^[46]. In China, ginger-salt-indirect moxibustion on CV8 (Shenque) is frequently applied to
16 treat UUI after stroke. Moxa cone moxibustion and moxa box moxibustion are primary forms of
17 ginger-salt-indirect moxibustion in clinical practices. Moxa cone moxibustion involves a moxa
18 cone burning directly on the ginger slice and provides thermal stimulus to the skin surface (see
19 Figure 2). Moxa box moxibustion facilitates manipulations and reduces adverse reactions by using
20 the device of moxa box with moxa sticks inside over the ginger slice (see Figure 3). Results of our
21 previous study^[47] showed that ginger-salt-partitioned moxibustion with moxa cone could reduce
22 mean daytime and nighttime voiding frequency in the treatment of urination disorders poststroke.
23 Besides, we also observed that ginger-salt-indirect moxibustion with moxa cones could increase
24 mean volume per void of UUI after stroke in an unpublished study. A recent cochrane review
25 concluded that ginger-salt-indirect moxibustion may be effective for UI after stroke and worth
26 further research^[47, 48].

32 **METHODS**

33 **Objectives**

34 This pilot study is to evaluate the feasibility of a research that assess the efficacy and safety of
35 ginger-salt-indirect moxibustion for UUI after stroke.
36

37 **Recruitment**

38 This is a multicenter, single-blinded, pilot randomized controlled trial. The research consists of
39 three sequential parts (see Figure 1): a recruitment period before randomization, a treatment period
40 for 4 weeks, and a follow-up period for 12 weeks. 120 eligible subjects will be recruited from
41 acupuncture wards of three hospitals according to the inclusion and exclusion criteria. During the
42 first visit, potentially qualified patients will be provided with detail information about this study,
43 including the research objective, study procedure, potential benefits and risks. If patient shows a
44 willingness to participate in, they will be required to sign a written informed consent. Baseline
45 assessment and randomization will be conduct afterwards.
46
47

48 **Design**

49 *Randomization and allocation concealment*

50 The randomization scheme is provided by Research Center of Clinical Epidemiology Affiliated to
51 Peking University Third Hospital in China. Statistical experts will adopt block randomization
52 method (block size of 6) of the SAS package (Version 9.1.3; SAS institute Inc., Cary, NC, USA)
53 to form the random allocation sequence. Then computer-generated opaque sealed envelopes with
54 serial number outside and group number inside will be produced. The envelopes will be kept in a
55 secure locked drawer making it inaccessible to all study personnel. After baseline assessments, the
56
57
58
59
60

1 envelopes should be opened sequentially by an independent researcher in front of the participants
2 to ensure adequate concealment. Participants will be allocated to the three groups according to the
3 group number printed inside the envelopes.
4
5
6

7 *Blinding*

8 Due to the feature of the moxibustion, it is difficult to make the therapists or participants blinded
9 to the allocation. Data managers and statisticians will be blinded throughout the trial. During the
10 intervention, therapists and data managers are requested not to communicate with each other about
11 the allocation. Blinded telephone interviewers will collect the follow-up materials to evaluate long
12 term effect of moxibustion at 16 weeks after the first moxibustion session.
13

14 **Participants**

15 *Sample size*

16 Because this is a pilot study, a power calculation to determine sample size was not conducted.
17 Sample size calculation will be performed basing on estimates of the number of participants we
18 would expect to recruit within 24 months. We therefore plan to recruit five participants per month,
19 according to our previous trial of ginger-salt-partitioned moxibustion for urination disorders after
20 stroke^[47]. A sample size of 40 per group and a total number of 120 will be included, which is
21 larger than the minimum of 12 per group suggested for pilot studies^[49]. Outcomes of this pilot
22 study will help calculate appropriate sample size for future randomized clinical trials.
23

24 *Inclusion criteria*

- 25 1. Male or female, aged 40- 75 years;
- 26 2. In-patients with UUI after stroke, according to the diagnosis criteria of the American Stroke
27 Association (ASA) and the International Continence Society (ICS);
- 28 3. 4th to 48th week after stroke onset;
- 29 4. Normal consciousness, communication ability and recognition;
- 30 5. Written informed consent.

31 *Exclusion criteria*

- 32 1. UUI caused by spinal injury, multiple sclerosis or hyperplasia of prostate gland;
- 33 2. Chronic urinary retention or UI before stroke onset;
- 34 3. Stress urinary incontinence, mixed urinary incontinence and chronic urinary tract infection;
- 35 4. Insufficiency of heart, liver, kidney organs;
- 36 5. Participants in another clinical trial.

37 **Intervention**

38 Ginger-Salt-Indirect Moxibustion is formulated on the basis of description in ancient literature and
39 our previous research^[47]. Moxibustion will be manipulated by certified acupuncturists with at least
40 20 years of clinical experiences. All treatment details will be standardized between practitioners
41 by guiding videos and relative trainings before the first acupuncture session. Interventions will be
42 performed in accordance with the STRICTOM^[50] and good clinical practice guidelines (GCP).
43

44 *Treatment group A*

45 Subjects of treatment group A will receive moxa cone moxibustion and routine care once a day for
46 4 weeks. The procedure of each session is described as follow (see figure 2). Participants are
47 asked to lie on a bed in a supine position and remove clothing to fully expose the navel in a room
48 with 25 to 30°C temperature. A certain amount of salt is put on the navel to cover the CV-8
49 (Shenque) and covered by a piece of fresh ginger slice (30mm in diameter and 4-5 mm in
50 thickness). Then a moxa cone (pure wormwood fiber in material; 15 mm in diameter and 30 mm
51
52
53
54
55
56
57
58
59
60

1
2
3 in length; Tongrentang Inc., China.) is placed on the fresh ginger slice and lit by the therapist.
4 Once the moxa cone is burnt out, therapist removes the whole moxa cone and replaces it with
5 another one. The technique requires a sensation of heat but no painful burning for participants. If
6 subjects feel insufferable pain or burning sensation, the ginger slice with burning moxa cone will
7 be removed immediately and reset after several minutes. Each session requires three units of moxa
8 cone. Therapist is required to observe the situation of patient and whisk away the burning ash to
9 avoid burning injury. This study is designed to evaluate moxibustion treatment as it is used in
10 normal practice. So moxibustion group will also receive the usual care provided to the control
11 group.

14 *Treatment group B*

15 Subjects of treatment group B will receive moxa box moxibustion and routine care once a day for
16 4 weeks. The manipulations are generally similar to treatment group A. The only difference is
17 that a double-holes moxa box (13 x 8 x 8.5 cm in volume) with two moxa sticks (pure wormwood
18 fiber, 15 mm in diameter and 70 mm in length; Tongrentang Inc., China.) in the holes will be
19 placed on the fresh ginger slice (see figure 3). The moxa sticks will be ignited from the bottom. If
20 patients feel pain, therapist will remove the lid with moxa sticks for several minutes. Each session
21 requires three units of moxa sticks.

24 *Control group*

25 According to pragmatic design, the control group will receive routine therapies for stroke recovery.
26 Routine therapies include control of blood pressure, inhibition of platelet aggregation, routine
27 physiotherapy, occupational therapy, glucose control treatment. Subjects in this group will be
28 encouraged to maintain their normal lifestyle, including diet, exercise and workload. Moreover,
29 participants will be suggested to inform the researchers of any new treatments performed after
30 entry into the trial.

33 **Outcome measures**

34 *Primary outcome measures*

35 Increase of mean volume per void at week 4 from the baseline, basing on the data of 72-hour
36 frequency-volume chart.

37 Mean volume per void is one of main quantitative indicators recorded in bladder dairies or
38 frequency volume charts^[19, 33, 51-53]. It is defined by dividing total volume of voluntary urination by
39 total frequency of voluntary urination in 72 hours in this study. Increase of mean volume per void
40 objectively reflects improvement of bladder capacity and detrusor stability in the urine filling and
41 storage period. In previous study, we observed that mean volume per void increased in
42 ginger-salt-indirect moxibustion group, comparing with control group with a statistical difference.
43 Consequently, we select increase of mean volume per void at week 4 from the baseline as primary
44 outcome to estimate efficacy of ginger-salt-indirect moxibustion on urination function of
45 participants. We assess increase of mean volume per at week 16 from the baseline to evaluate
46 long-term efficacy as well.

51 *Secondary outcome measures*

- 52 1. The mean frequency of urination per day, including voluntary and incontinence urination.
- 53 2. Quality of life assessments measured by completion of the Incontinence Quality of Life
54 Questionnaire (I-QOL)^[54] and the Barthel Index (BI)^[55] in Chinese version.

55 The average frequency of urination per day is composed of mean frequency of voluntary and
56 incontinent urination, which represents reduction in frequent micturition and urinary incontinence.
57
58
59
60

This outcome measure is strongly linked to stability of bladder and detrusor. Questionnaires for quality of life assessment will be completed basing on objective condition and subjective sensation of participants.

All outcome measures will be assessed at before the first moxibustion session, at 4 weeks and 16 weeks after the first moxibustion session.

Adverse events

Adverse events are defined as negative or unintended clinical manifestation following the treatments. Common adverse events such as allergy, burn and infection are reported by a systematic review^[56]. Adverse reactions should be reported by patients or caregivers and solved by the therapists.

Data management

Before recruitment, the whole research group, including therapists, data administrators and outcome assessors, will participate in a training seminar about research contents and data management. Baseline characteristics of participants will be recorded on Case Report Forms (CRFs) by a research assistant. Data collection of urination and questionnaires will be conducted by a researcher who remains blinded to the group allocation at the baseline, 4 and 16 weeks after first moxibustion session. Occupational caregivers will be trained to identify urinary incontinence and voluntary urination. Caregivers will collect urine of voluntary urination and measure it with a pot-shaped urine collector with scales. They will be required to record accurate voiding time, voluntary urinary volume and urinary incontinence episodes on a 72-hour frequency-volume chart (see Figure 4). The record should be started at 8AM and last for 72 hours. If caregivers failed to collect urine in time, they will note voiding time and specific reasons on the chart. The blinded researcher will complete the urination section on CRFs according to the 72-hour frequency-volume charts handed in by caregivers.

Two independent researchers blinded to the group allocation will enter the data into Excel spreadsheet after the completion of the CRFs separately. Another independent researcher will compare the two data sets to check up errors. If different data entry is discovered, data will be compared with the original CRF to verify inconsistency. All modification will be marked on the CRFs. Research data will be gathered and saved abiding by the Data Protection Act 1998. Paper files will be kept in a locked filing cabinet and electronic documents will be stored in a password protected computer, with access restricted to primary research personnel. All research documents will be preserved for at least 5 years after publication.

Statistical analysis

Data analysis will be performed in a blinded pattern by statisticians of Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical analyses will be conducted on an intention-to-treat basis using the SPSS statistical package program (ver.18.0). Missing data will be replaced in accordance with the principle of the last observation carried forward. A P value < 0.05 is considered statistically significant with two-sided test. Baseline characteristics including gender, age and previous duration are described as n (%) for categorical data and mean ± SD (standard deviation) for continuous data. To compare the differences among groups, we will perform analysis of variance (ANOVA) for normally distributed data, Kruskal-Wallis test for abnormally distributed data and chi-squared test for categorical data. Comparisons between two groups will be conducted using bonferroni method of post hoc multiple comparisons.

Ethical considerations

This study adheres to the principles of the Declaration of Helsinki and has been approved by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). We will conduct the research in the following hospitals: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing Huguosi Hospital of Traditional Chinese Medicine and China Rehabilitation Research Center. Each participant will sign written informed consents voluntarily.

DISCUSSION

Exploration of UI dates back to the era of Yellow Emperor's Inner Canon in China. The term of UI after stroke was first recorded in “JingYueQuanShu”, a Chinese ancient book by Zhang Jiebin. Ancient physicians began to realize that apoplexy was one of the causes of UI since then. In the theory of traditional Chinese medicine (TCM), kidney qi could regulate voiding function and ensure voluntary urination. Deficiency of kidney qi was known to be the primary pathogenesis referring to “ZhuBingYuanHouLun”, a famous ancient TCM literature. Ginger and salt are able to warm and tonify the kidney Qi in TCM theory. Shenque (CV8) is applied as a principal acupoint for nourishing kidney Qi, which is only allowed to be used with moxibustion. Owing to the features of materials and usage, ginger-salt-indirect moxibustion is likely to warm and nourish kidney Qi, thereby controlling bladder and regulating voiding function.

Placebo or sham control is encouraged in clinical trials to avoid bias^[57]. To our knowledge, no consensus has been established to recommend valid placebo or sham methods of moxibustion by far. Sham moxibustion is impractical to achieve blinding because of the common cognition of moxibustion in Chinese patients. Because of preference for moxibustion, incompliance of Chinese patients will make it difficult to use standard therapies as control treatment. With the pragmatic purpose, we set a usual care group as a blank control group, rather than a certain effective therapy or a sham device.

Concerning evaluation instruments, we select 72-hour frequency-volume chart to record urination details and I-QOL together with Barthel Index to assess quality of life. The frequency volume chart and bladder diary is highly recommended in clinical trials by ICS^[1]. Frequency-volume chart records the time and volume of each voiding, as well as incontinence episodes. ICS suggested that frequency-volume chart should be recorded for at least 24 hours^[1]. Recent literatures^[51, 58-61] considered that a minimum of 72 hours is required to ensure reliability for diary parameters. Thus, we use a 72-hour frequency-volume chart to alleviate burdens of patients and improve compliance^[62, 63].

As for the assessment of quality of life, I-QOL is strongly recommended to assess the effect of urinary incontinence on patients' status^[64]. A recent research^[54] has affirmed the reliability and validity of I-QOL as an incontinence-related QOL instrument in neurogenic UI patients. The items of I-QOL focus on three dimensions, namely social embarrassment, avoidance behaviors and psychosocial impacts, without physical mobility and self-care ability. Barthel Index is added to evaluate patients' activities of daily living, which is recognized as a valid and reliable outcome measurement for stroke survivors^[55].

One limitation of this pilot study is that we fail to prevent therapists and participants from knowing the group allocation because of the characteristics of moxibustion. To minimize the bias, acupuncturists will receive professional training and strict quality control. In order to homogenize the psychological effects, participants are informed that effects of two moxibustion techniques are

1
2
3 uncertain. The words ‘placebo’ or ‘control’ will be avoided. Similar strategies have been applied in
4 previous trials^[65, 66]. Noncompliance of the control group is another deficiency of this pilot trial
5 and may lead to a high drop-out rate. We will solve this problem by providing participants with
6 financial compensations and free moxibustion therapies after the completion of the entire trial.
7

8 This study is the major sub-project focusing on stroke recovery, which is sponsored and funded
9 by National Administration of Traditional Chinese Medicine of China. This protocol describes the
10 first pilot randomized controlled trial evaluating the feasibility of a research that assess the
11 curative effects and safety of ginger-salt-indirect moxibustion on UUI after stroke. Results of this
12 preliminary study will provide essential information for the design of subsequent large-scale trials.
13

14 **Trial status**

15 The trial is currently in the recruitment phase.
16

17 **Author affiliations**

18 ¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital
19 Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China
20

21 ²Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital, China
22

23 **Contributors** LPW and HLL conceived this study and prepared the initial protocol. LLW drafted the manuscript
24 and participated in design of the study. GXS, YY, LZ, TZ participated in revising the protocol. LZ plans for the
25 statistical analysis. LPW and HLL made amendments of the trial protocol. All authors read and approved the final
26 manuscript.
27

28 **Funding** The trial is sponsored and funded by special project for the national clinical research bases construction
29 of traditional Chinese medicine belonging to the State Administration of Traditional Chinese Medicine of the
30 People's Republic of China, grant number: JD2X2012152.
31

32 **Ethics approval** Research ethics approval was attained from the Research Ethical Committee of Beijing
33 Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094).
34

35 **Competing interests** None.
36

37 **REFERENCES**


- 38 1. Abrams P, Andersson KE, Birder L, *et al*. Fourth International Consultation on Incontinence
39 Recommendations of the International Scientific Committee: Evaluation and treatment of urinary
40 incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn* 2010;29:213-240.
- 41 2. Brittain KR, Peet SM, Potter JF, *et al*. Prevalence and management of urinary incontinence in
42 stroke survivors. *Age Ageing* 1999;28:509-511.
- 43 3. Marinkovic SP, Badlani G: Voiding and sexual dysfunction after cerebrovascular accidents. *J*
44 *Urol* 2001;165:359-370.
- 45 4. Barrett J: Bladder and bowel problems after stroke. *Reviews in Clinical Gerontology* 12:253-267.
- 46 5. Williams MP, Srikanth V, Bird M, *et al*: Urinary symptoms and natural history of urinary
47 continence after first-ever stroke--a longitudinal population-based study. *Age Ageing*
48 2012;41:371-376.
- 49 6. Santiagu SK, Arianayagam M, Wang A, *et al*: Urinary incontinence-pathophysiology and
50 management outline. *Aust Fam Physician* 2008;37:106-110.
- 51 7. Tapia CI, Khalaf K, Berenson K, *et al*: Health-related quality of life and economic impact of
52 urinary incontinence due to detrusor overactivity associated with a neurologic condition: a
53
54
55
56
57
58
59
60

- systematic review. *Health Qual Life Outcomes* 2013;11:13.
8. Gelber DA, Good DC, Laven LJ, *et al*: Causes of urinary incontinence after acute hemispheric stroke. *Stroke* 1993;24:378-382.
 9. Mehdi Z, Birns J, Bhalla A: Post-stroke urinary incontinence. *Int J Clin Pract* 2013; 67:1128-1137.
 10. Manack A, Motsko SP, Haag-Molkenteller C, *et al*: Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. *Neurourol Urodyn* 2011;30:395-401.
 11. Nakayama H, Jorgensen HS, Pedersen PM, *et al*: Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. *Stroke* 1997;28:58-62.
 12. Anderson CS, Jamrozik KD, Broadhurst RJ, *et al*: Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke* 1994;25:1935-1944.
 13. Patel M, Coshall C, Rudd AG, *et al*: Natural history and effects on 2-year outcomes of urinary incontinence after stroke. *Stroke* 2001;32:122-127.
 14. Kolominsky-Rabas PL, Hilz MJ, Neundoerfer B, *et al*: Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. *Neurourol Urodyn* 2003;22:322-327.
 15. Dumoulin C, Korner-Bitensky N, Tannenbaum C: Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil* 2005;12:66-76.
 16. Gross JC: A comparison of the characteristics of incontinent and continent stroke patients in a rehabilitation program. *Rehabil Nurs* 1998;23:132-140.
 17. Hu TW, Wagner TH, Bentkover JD, *et al*: Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology* 2004;63:461-465.
 18. Levy R, Muller N: Urinary incontinence: economic burden and new choices in pharmaceutical treatment. *Adv Ther* 2006;23:556-573.
 19. Wyman JF, Burgio KL, Newman DK: Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. *Int J Clin Pract* 2009;63:1177-1191.
 20. Godec CJ: "Timed voiding"--a useful tool in the treatment of urinary incontinence. *Urology* 1984;23:97-100.
 21. DK N: Conservative therapy for incontinence. In: *Female Urology: a Practical Clinical Guide*. Edited by Goldman, HB VS. New York: Humana Press; 2007: 63-79.
 22. Beetz R: Mild dehydration: a risk factor of urinary tract infection? *Eur J Clin Nutr* 2003;57:S52-S58.
 23. DK N: Lifestyle interventions. In: *Pelvic Floor Disorders*. Edited by Bourcier AP ME, P A. Philadelphia: Elsevier Saunders; 2004: 269-276.
 24. Koskimaki J, Hakama M, Huhtala H, *et al*: Association of smoking with lower urinary tract symptoms. *J Urol* 1998;159:1580-1582.
 25. Kinnunen O: Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)* 1991;3:161-170.
 26. Richter HE, Creasman JM, Myers DL, *et al*: Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct* 2008;19:1653-1658.
 27. Milne JL: Behavioral therapies for overactive bladder: making sense of the evidence. *J Wound Ostomy Continence Nurs* 2008;35:93-101, 102-103.

28. Burgio KL: Behavioral treatment options for urinary incontinence. *Gastroenterology* 2004;126:S82-S89.
29. Burgio KL: Current perspectives on management of urgency using bladder and behavioral training. *J Am Acad Nurse Pract* 2004;16:4-7.
30. Burgio KL, Goode PS, Locher JL, *et al*: Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. *JAMA* 2002;288:2293-2299.
31. Burgio KL, Locher JL, Goode PS, *et al*: Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA* 1998;280:1995-2000.
32. Wyman JF, Fantl JA, McClish DK, *et al*: Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. *Am J Obstet Gynecol* 1998;179:999-1007.
33. Mattiasson A, Blaakaer J, Hoyer K, *et al*: Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. *Bju Int* 2003;91:54-60.
34. Brown JH LN: Muscarinic receptor agonists and antagonists. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. Edited by Brunton L CBCB, 12th ed edn. New York: McGraw-Hill;2011: 219-237.
35. Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. *Bju Int* 2007;100:987-1006.
36. Lam S, Hilas O: Pharmacologic management of overactive bladder. *Clin Interv Aging* 2007;2:337-345.
37. Novara G, Galfano A, Secco S, *et al*: A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol* 2008;54:740-763.
38. Chapple CR: Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology* 2000;55:33-46, 50.
39. Chapple C, Khullar V, Gabriel Z, *et al*: The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. *Eur Urol* 2005;48:5-26.
40. Chapple CR, Khullar V, Gabriel Z, *et al*: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. *Eur Urol* 2008;54:543-562.
41. George A: Management of Urinary Incontinence. *P&T* 2012;6:345-361.
42. Thomas LH, Watkins CL, French B, *et al*: Study protocol: ICONS: identifying continence options after stroke: a randomised trial. *Trials* 2011;12:131.
43. Thomas LH, Barrett J, Cross S, *et al*: Prevention and treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev* 2005:D4462.
44. Dong H ZX: An overview of traditional Chinese medicine. Traditional Medicine in Asia. In: *New Delhi: World Health Organisation*. Edited by Chaudhary RR RU: Regional Office South -East Asia; 2002: 17-30.
45. H. Qinfeng WHLJ: Bibliometric analysis of diseases spectrum of moxibustion therapy. *Journal of Acupuncture and Tuina Science* 2012;6:334-342.
46. Deng H, Shen X: The Mechanism of Moxibustion: Ancient Theory and Modern Research. *Evid Based Complement Alternat Med* 2013:379291.
47. Liu HL, Wang LP: [Randomized controlled study on ginger-salt-partitioned moxibustion at shenque (CV 8) on urination disorders poststroke]. *Zhongguo Zhen Jiu* 2006;26:621-624.
48. Thomas LH, Cross S, Barrett J, *et al*: Treatment of urinary incontinence after stroke in adults.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Cochrane Database Syst Rev* 2008:D4462.
49. SA J: Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut Statist* 2005;287-291.
50. Cheng CW, Fu SF, Zhou QH, *et al*: Extending the CONSORT Statement to moxibustion. *J Integr Med* 2013;11:54-63.
51. Schick E, Jolivet-Tremblay M, Dupont C, *et al*: Frequency-volume chart: the minimum number of days required to obtain reliable results. *Neurourol Urodyn* 2003;22:92-96.
52. Lucas MG, Bosch RJ, Burkhard FC, *et al*: EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur Urol* 2012;62:1130-1142.
53. Ku JH, Jeong IG, Lim DJ, *et al*: Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. *Neurourol Urodyn* 2004;23:331-335.
54. Wagner TH, Patrick DL, Bavendam TG, *et al*: Quality of life of persons with urinary incontinence: development of a new measure. *Urology* 1996;47:67-72.
55. Duffy L, Gajree S, Langhorne P, *et al*: Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. *Stroke* 2013;44:462-468.
56. Park JE, Lee SS, Lee MS, *et al*: Adverse events of moxibustion: a systematic review. *Complement Ther Med* 2010;18:215-223.
57. Ernst E: Testing traditional cupping therapy. *J Pain* 2009;10:555.
58. Yap TL, Cromwell DC, Emberton M: A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. *Bju Int* 2007;99:9-16.
59. Brown JS, McNaughton KS, Wyman JF, *et al*: Measurement characteristics of a voiding diary for use by men and women with overactive bladder. *Urology* 2003;61:802-809.
60. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, *et al*: The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. *Neurourol Urodyn* 2013; 22:1-5.
61. Bright E, Cotterill N, Drake M, *et al*: Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. *Eur Urol* 2014;66:294-300.
62. Groutz A, Blaivas JG, Chaikin DC, *et al*: Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol* 2000;164:698-701.
63. Tincello DG, Williams KS, Joshi M, *et al*: Urinary diaries: a comparison of data collected for three days versus seven days. *Obstet Gynecol* 2007;109:277-280.
64. Avery KN, Bosch JL, Gotoh M, *et al*: Questionnaires to assess urinary and anal incontinence: review and recommendations. *J Urol* 2007;177:39-49.
65. Linde K, Dincer F: How informed is consent in sham-controlled trials of acupuncture? *J Altern Complement Med* 2004;10:379-385.
66. Shi GX, Han LL, Liu LY, *et al*: Acupuncture at local and distant points for tinnitus: study protocol for a randomized controlled trial. *Trials* 2012;13:224.

Figure 1 Trial profile



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Moxa cone moxibustion



view only

Figure 3. Moxa box moxibustion



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

72-hour frequency-volume chart

Date	Time (a.m/p.m)	Volume voided (ml)	urinary incontinence (tick in the blank)	notes

BMJ Open

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006326.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Sep-2014
Complete List of Authors:	Wang, Linpeng; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Wang, Lichen; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Shi, Guangxia; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Zeng, Lin; Peking University Third Hospital, Research Center of Clinical Epidemiology Yang, Yi; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Zhang, Tao; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Liu, Hiulin; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Urology, Neurology, Complementary medicine, Rehabilitation medicine
Keywords:	Urinary incontinences < UROLOGY, Neurology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

LinPeng Wang¹, Lichen Wang¹, GuangXia Shi¹, Lin Zeng², Yi Yang¹, Tao Zhang¹, HuiLin Liu^{1*}

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University, Beijing, China

Correspondence to Dr. Hui-Lin Liu*; lhlxwy@aliyun.com

ABSTRACT

Introduction: Ginger-salt-indirect moxibustion is widely applied to treat urge urinary incontinence after stroke, which is a common complication in stroke survivors. Moxa cone moxibustion and moxa box moxibustion are main techniques of ginger-salt-indirect moxibustion. Our previous study had shown that ginger-salt-indirect moxibustion using moxa cones was feasible and effective for urination disorders post-stroke. This pilot study aims to assess the feasibility of conducting research to evaluate the efficacy and safety of ginger-salt-indirect moxibustion for patients with post-stroke urge urinary incontinence.

Methods and analysis: This is a multicenter, prospective, single-blinded, pilot randomized controlled trial. 120 eligible patients will be randomly allocated to three groups. Treatment group A (n = 40) will receive moxa cone moxibustion and routine care; treatment group B (n = 40) will receive moxa box moxibustion and routine care; control group (n = 40) will only receive routine care for stroke recovery. The entire moxibustion treatment will consist of a total of 28 sessions during the course of 4 weeks. Primary outcome measure will be increase of mean volume per void assessed at week 4 from the baseline, based on the data of a 72-hour frequency-volume chart. Secondary outcome measures will include mean frequency of urination per day and quality of life assessments measured by completion of Incontinence Quality of Life Questionnaire and Barthel Index. All outcome measures will be assessed before the first moxibustion session (baseline), at 4 weeks and 16 weeks from baseline. Adverse events in three groups will be recorded to assess safety of moxibustion.

Ethics and dissemination: Research ethics was approved by Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). Written informed consent will be obtained from all participants. Study results will be published in peer-reviewed journals.

Trial Registration number: ISRCTN 44706974.

Strengths and limitations of this study

First pilot study to evaluate the feasibility of conducting research to assess the efficacy and safety of ginger-salt-indirect moxibustion as treatment for urge urinary incontinence after stroke
Multicentre, randomised controlled trial with pragmatic design
Interventions conducted by certified acupuncturists according to the STRICTOM and GCP.
Lack of blinding of acupuncturists and participants

INTRODUCTION

Urinary incontinence (UI) is defined as involuntary leakage of urine that causes hygienic or social problems by International Continence Society (ICS) [1]. Prevalence of UI after stroke varies from 32–79% at admission [2–4], 25% at hospital discharge and 15% after one year [4]. Urge urinary incontinence (UUI) is a common type of UI [5] after stroke. It is characterized by involuntary leakage of urine accompanied or preceded by urgency [1].

Results of previous review [6] suggested that there were three major causes of urinary incontinence after stroke: detrusor hyperreflexia caused by infarction; stroke-related cognitive or language deficits; bladder hyporeflexia with resultant overflow incontinence. UUI can be caused by detrusor overactivity due to the loss of inhibitory neurons after stroke [7]. Detrusor overactivity is characterized by involuntary detrusor contractions during the filling and storage phase [1, 7, 8]. When intra-detrusor pressure generated by abnormal detrusor contractions exceeds sphincter pressure, urinary incontinence occurs [7]. UI is a strong prognostic indicator for stroke recovery, which is associated with high rates of mortality [9, 10], disability [11] and increasing admission to institutional care [12]. Micturition disorders may result in urinary infection, nephritis, fungal dermatitis [13], and even bedsore. Typical symptoms, including frequent micturition, nocturia and urgency, could lead to impaired quality of life [14] and heavy economic burdens [15, 16].

Initial treatments for UUI after stroke recommended by ICS are behavioral therapy and pharmacotherapy [1]. Behavioral therapies, including healthy bladder habits and training techniques, aim at changing patients' lifestyle and at teaching patients to control urgency and enhance continence ability [17]. For habit modification, patients are guided to re-establish a healthy voiding schedule, eliminate bladder irritants from the diet, manage fluid intake and bowel regularity, control weight and give up smoking [18–24]. Training techniques consist of bladder training, urgency control techniques, pelvic muscle exercises, delayed voiding and multicomponent behavioral training [17]. Behavioral interventions are applied in the primary care setting, with or without pharmacotherapy [25–27]. Among these strategies, behavioral training and bladder training have the strongest efficacy evidence for the treatment of UUI [28–31]. Antimuscarinic drugs can reduce urgency and improve bladder function by controlling detrusor muscle overactivity through inhibition of M2 and M3 muscarinic bladder receptors on bladder [32–34]. Several meta-analyses

1
2
3 have shown that the most widely used antimuscarinic drugs have significant clinical benefits on
4 UUI^[35-38]. However, use of antimuscarinic agents is complicated by dose convenience, drug
5 contraindication and financial concerns^[39]. A Cochrane systematic review^[40] concluded that no
6 studies designed to manage urinary incontinence after stroke in secondary care had been
7 rigorously conducted by far. Although there is clinical guideline for the management of urinary
8 incontinence after stroke^[1], to date there is insufficient good quality evidence to support the
9 current clinical practices^[41]. More available therapies and well-designed studies are required to
10 provide further evidences for management of UUI after stroke.

11
12 Moxibustion is a therapy using ignited materials (usually moxa) to heat selected points of the
13 skin surface. This therapy is widely used for chronic deficiency diseases^[42] and is commonly
14 indicated for UUI^[43]. The mechanism of action of moxibustion combines thermal, radiation and
15 pharmacological effects of the materials used, acting on the meridian system^[44]. Following the
16 theory of Traditional Chinese Medicine (TCM), kidney *qi* regulates voiding function and ensures
17 voluntary urination. Deficiency of kidney *qi* is known to be the primary pathogenesis of UI
18 according to “ZhuBingYuanHouLun” (a famous ancient TCM literature). Ginger and salt are
19 typically used on *Shenque* (CV8) acupoint to warm, tonify and nourish the kidney *qi* thereby
20 controlling bladder and regulating voiding function.

21 Moxa cone moxibustion and moxa box moxibustion are primary techniques of
22 ginger-salt-indirect moxibustion commonly used in clinical practices in China. Moxa cone
23 moxibustion involves a moxa cone burning directly on the ginger slice and providing thermal
24 stimulus to the skin surface (see Figure 2). Moxa box moxibustion facilitates manipulations and
25 reduces adverse reactions by using the device of moxa box with moxa sticks inside over the ginger
26 slice (see Figure 3). Results of our previous study^[45] showed that ginger-salt-partitioned
27 moxibustion with moxa cone could reduce mean daytime and nighttime voiding frequency in the
28 treatment of urination disorders poststroke. In addition, we also observed that ginger-salt-indirect
29 moxibustion with moxa cones could increase mean volume per void of UI after stroke in an
30 unpublished study. Our previous studies, together with results from an earlier Cochrane review^{[40,}
31 ^{45]} suggest ginger-salt-indirect moxibustion may be worth investigating with a more rigorous study
32 design.

33 METHODS

34 Objectives

35 This pilot study is to evaluate the feasibility of a research to assess the efficacy and safety of
36 ginger-salt-indirect moxibustion for the treatment of UUI after stroke.

37 Recruitment

38 This is a multicenter, single-blinded, pilot randomized controlled trial. The research consists of
39 three sequential parts (see Figure 1): a recruitment period before randomization, a treatment period
40 of 4 weeks, and a follow-up period of 12 weeks. 120 eligible participants will be recruited from
41 acupuncture wards of three hospitals according to the inclusion and exclusion criteria. During the
42 first visit, potentially qualified patients will be provided with detailed information about this study,
43 including the research objective, study procedure, potential benefits and risks. If a patient shows
44 willingness to participate, they will be required to sign a written informed consent. This will be
45 followed by baseline assessment and randomization.

46 Design

Randomization and allocation concealment

The randomization scheme is provided by the Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical experts will use the block randomization method (block size of 6) of the SAS package (Version 9.1.3; SAS institute Inc., Cary, NC, USA) to form the random allocation sequence. Then computer-generated opaque sealed envelopes with serial number outside and group number inside will be produced. The envelopes will be kept in a secure locked drawer making it inaccessible to all study personnel. After baseline assessments, the envelopes will be opened sequentially by an independent researcher in front of the participants to ensure adequate concealment. Participants will be allocated to the three groups according to the group number printed inside the envelopes.

Blinding

Due to the feature of the moxibustion, it is difficult to make the therapists or participants blinded to the allocation. Data managers and statisticians will be blinded throughout the trial. During the intervention, therapists and data managers are requested not to communicate with each other about the allocation. Blinded telephone interviewers will collect the follow-up materials to evaluate long term effect of moxibustion at 16 weeks after the baseline.

Participants

Sample size

Because this is a pilot study, a power calculation to determine sample size was not conducted. Sample size calculation was performed based on estimates of the number of participants we would expect to recruit within 24 months. We therefore plan to recruit five participants per month, according to our previous trial. A sample size of 40 per group and a total number of 120 will be included, which is larger than the minimum of 12 per group suggested for pilot studies^[46]. Outcomes of this pilot study will help calculate appropriate sample size for further randomized clinical trials.

Inclusion criteria

1. Male or female, aged 40- 75 years;
2. In-patients with UUI after stroke, according to the diagnosis criteria of the American Stroke Association (ASA) and the International Continence Society (ICS);
3. 4th to 48th week after stroke onset;
4. Normal consciousness, communication ability and recognition;
5. Written informed consent.

Exclusion criteria

1. UUI caused by spinal injury, multiple sclerosis or hyperplasia of prostate gland;
2. Chronic urinary retention or UI before stroke onset;
3. Stress urinary incontinence, mixed urinary incontinence and chronic urinary tract infection;
4. Insufficiency of heart, liver, kidney organs;
5. Participants in another clinical trial.

Discontinuation criteria

Reasons for discontinuation of treatment may include, but are not limited to, the following:

1. Participants' decision of discontinuation of treatment at any time for any reason;
2. Investigators' determination to discontinue the treatment for patient's safety and best interests at any time;
3. Non-compliance of participants with the study procedure (eg, study visits);

4. Concomitant therapy that could affect the study results during the trial;
5. Detection of protocol violations at any time.

Intervention

Ginger-Salt-Indirect Moxibustion is formulated on the basis of description in ancient literature and our clinical experience. Moxibustion will be manipulated by certified acupuncturists with at least 20 years of clinical experience. All treatment details will be standardized between practitioners by guiding videos and relative trainings before the first acupuncture session. Interventions will be performed in accordance with the STRICTOM^[47] and good clinical practice guidelines (GCP).

Treatment group A

Participants in treatment group A will receive moxa cone moxibustion and routine care once a day for 4 weeks. The procedure of each session as it is used in normal practices is described as follows (see figure 2). Participants are asked to lie on a bed in a supine position and remove clothing to fully expose the navel in a temperature controlled room (25 to 30°C). A certain amount of salt is put on the navel to cover *Shenque* (CV8) acupoint and covered by a piece of fresh ginger slice (30mm in diameter and 4-5 mm in thickness). Then a moxa cone (pure wormwood fiber in material; 15 mm in diameter and 30 mm in length; Tongrentang Inc., China.) is placed on the fresh ginger slice and lit by the therapist. Once the moxa cone is burnt out, the therapist removes the whole moxa cone and replaces it with another one. The technique requires a sensation of heat but no painful burning sensation for participants. If participants feel pain or a burning sensation, the ginger slice with burning moxa cone will be removed immediately and reset after several minutes. Each session requires three units of moxa cone. The therapist is required to carefully observe the patient and whisk away the burning ash to avoid burning injury. This study is designed to evaluate moxibustion treatment as it is used in normal practice. The moxibustion group will also receive the usual care provided to the control group.

Treatment group B

Participants in treatment group B will receive moxa box moxibustion and routine care once a day for 4 weeks. The manipulations are generally similar to those in treatment group A. The only difference is that the double-holes moxa box (13 x 8 x 8.5 cm in volume) with two moxa sticks (pure wormwood fiber; 15 mm in diameter and 70 mm in length; Tongrentang Inc., China.) in the holes will be placed on the fresh ginger slice (see figure 3). The moxa sticks will be ignited from the bottom. If patients feel pain, the therapist will remove the lid with the moxa sticks for several minutes. Each session requires three units of moxa sticks.

Control group

According to pragmatic design, the control group will receive routine therapies for stroke recovery. These include control of blood pressure, inhibition of platelet aggregation, routine physiotherapy, occupational therapy and glucose control treatment. Participants in this group will be suggested to maintain their normal lifestyle, including diet, exercise and workload. Moreover, participants will be encouraged to inform the researchers of any new treatments performed after entry into the trial.

Outcome measures

Primary outcome measures

Increase of mean volume per void at week 4 from baseline, based on 72-hour frequency-volume chart data.

Mean volume per void is one of the main quantitative indicators recorded in bladder dairies or frequency volume charts^[17, 31, 48-50]. It is calculated by dividing total volume of voluntary urination

1
2
3 by total frequency of voluntary urination in 72 hours. Increase of mean volume per void
4 objectively reflects improvement of bladder capacity and detrusor stability in the urine filling and
5 storage period. In a previous study, we observed that mean volume per void increased in the
6 ginger-salt-indirect moxibustion group, compared to the control group with a statistical difference.
7 Consequently, we selected increase of mean volume per void at week 4 from the baseline as
8 primary outcome. We will assess increase of mean volume per void at week 16 from the baseline
9 to evaluate long-term efficacy as well.

10 11 *Secondary outcome measures*

- 12 1. The mean frequency of urination per day, including voluntary and incontinence urination.
- 13 2. Quality of life assessments measured by completion of the Incontinence Quality of Life
14 Questionnaire (I-QOL)^[51] and the Barthel Index (BI)^[52].

15
16 The average frequency of urination per day is composed of mean frequency of voluntary and
17 incontinent urination, which represents the severity of frequent micturition and urinary
18 incontinence respectively. This is strongly linked to stability of bladder and detrusor.
19 Questionnaires for quality of life assessment will be completed based on objective condition and
20 subjective sensation of participants.

21 All outcome measures will be assessed before the baseline, at 4 weeks and 16 weeks from the
22 baseline.

23 24 *Adverse events*

25 Adverse events (AEs) are defined as negative or unintended clinical manifestation following the
26 treatments. Participants will be instructed to report any abnormal reactions to the clinical research
27 team at any time. In addition, study investigators will collect information about abnormal
28 reactions weekly by visiting the participants. All details of related and unexpected AEs, such as
29 time of occurrence, degree and suspected causes, will be recorded on Case Report Forms (CRFs).
30 The common AEs related to moxibustion include allergy, burn and infection^[53]. AEs will be
31 classified into 5 grades: Mild (asymptomatic or mild symptoms; clinical or diagnostic
32 observations only; intervention not indicated); Moderate (minimal, local or noninvasive
33 intervention indicated); Severe (severe or medically significant but not immediately
34 life-threatening; hospitalization or prolongation of hospitalization indicated); Very severe
35 (life-threatening consequences; urgent intervention indicated); Death related to adverse events.
36 Participants with mild and moderate AEs will receive symptomatic treatment and will be closely
37 followed up by the research team. Severe AEs will be reported to the Research Ethics Committee
38 within 48 hours. The Research Ethics Committee will offer medical advice to the research team
39 and determine whether the patient is eligible for further treatment.

40 41 **Data management**

42 Before recruitment, the whole research group, including therapists, data administrators and
43 outcome assessors, will participate in a training seminar about research contents and data
44 management. Baseline characteristics of participants will be recorded on CRFs by a research
45 assistant. Data collection of urination and questionnaires will be conducted by a researcher who
46 remains blinded to the group allocation at the baseline, 4 and 16 weeks after the baseline.
47 Occupational caregivers will be trained to identify urinary incontinence and voluntary urination.
48 Caregivers will collect urine of voluntary urination and measure it with a pot-shaped urine
49 collector with scales. They will be trained to record accurate voiding time, voluntary urinary
50 volume and urinary incontinence episodes on a 72-hour frequency-volume chart (see Figure 4).
51
52
53
54
55
56
57
58
59
60

1
2
3 The record will be started at 8AM and last for 72 hours. If caregivers failed to collect urine in time,
4 they will note voiding time and specific reasons on the chart. The blinded researcher will complete
5 the urination section on CRFs according to the 72-hour frequency-volume charts handed in by
6 caregivers.
7

8 Two independent researchers blinded to the group allocation will enter the data on Excel
9 spreadsheet after the completion of the CRFs separately. Another independent researcher will
10 compare the two data sets for check-up. If different data entry is discovered, data will be
11 compared with the original CRFs to verify inconsistency. All modification will be marked on the
12 CRFs. Research data will be gathered and saved abiding by the Data Protection Act 1998. Paper
13 files will be kept in a locked filing cabinet and electronic documents will be stored in a password
14 protected computer, with access restricted to the principal investigator. All research documents
15 will be preserved for at least 5 years after publication.
16

17 **Statistical analysis**

18 Data analysis will be performed in a blinded pattern by statisticians of Research Center of Clinical
19 Epidemiology Affiliated to Peking University Third Hospital in China. Statistical analyses will be
20 conducted on an intention-to-treat basis using the SPSS statistical package program (ver.18.0).
21 Missing data will be replaced in accordance with the principle of the last observation carried
22 forward. A P value < 0.05 will be considered statistically significant with two-sided test. Baseline
23 characteristics including gender, age and previous duration are described as n (%) for categorical
24 data and mean ± SD (standard deviation) for continuous data. To compare the differences among
25 groups, we will perform analysis of variance (ANOVA) for normally distributed data,
26 Kruskal-Wallis test for abnormally distributed data and chi-squared test for categorical data.
27 Comparisons between two groups will be conducted using Bonferroni method of post hoc multiple
28 comparisons.
29

30 **Ethical considerations**

31 This study adheres to the principles of the Declaration of Helsinki and has been approved by the
32 Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to
33 Capital Medical University (ref: 2013BL-094). We will conduct the research in the following
34 hospitals: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University,
35 Beijing Huguosi Hospital of Traditional Chinese Medicine and China Rehabilitation Research
36 Center. Each participant will sign written informed consents voluntarily.
37

38 **DISCUSSION**

39 Placebo or sham control is encouraged in clinical trials to avoid bias^[54]. To our knowledge, no
40 consensus has been established to recommend valid placebo or sham methods of moxibustion by
41 far. Sham moxibustion is impractical to achieve blinding because of the common knowledge of
42 moxibustion in Chinese patients. Because of preference for moxibustion, incompletion of Chinese
43 patients will make it difficult to use standard therapies as control treatment. Following pragmatic
44 purpose, we set a usual care group as a blank control group, rather than a certain effective therapy
45 or a sham device.
46

47 Concerning evaluation instruments, we selected 72-hour frequency-volume chart to record
48 urination details and I-QOL together with Barthel Index to assess quality of life. The frequency
49 volume chart and bladder diary is highly recommended in clinical trials by ICS^[1].
50 Frequency-volume charts record the time and volume of each voiding, as well as incontinence
51
52
53
54
55
56
57
58
59
60

1
2
3 episodes. ICS suggested that frequency-volume charts should be recorded for at least 24 hours^[1].
4 A minimum of 72 hours was required to ensure reliability for diary parameters^[48, 55-58]. Thus, we
5 will use a 72-hour frequency-volume chart to alleviate burdens for patients and improve
6 compliance^[59, 60].
7

8 As for the assessment of quality of life, I-QOL is strongly recommended to assess the effect of
9 urinary incontinence on patients' quality of life^[61]. Previous research^[51] has affirmed the reliability
10 and validity of I-QOL as an incontinence-related QOL instrument in neurogenic UI patients. The
11 items of I-QOL focus on three dimensions, namely social embarrassment, avoidance behaviors
12 and psychosocial impacts, without physical mobility and self-care ability. Barthel Index is added
13 to evaluate patients' activities of daily living, which is recognized as a valid and reliable outcome
14 measurement for stroke survivors^[52].
15

16 One limitation of this pilot study is that we will be unable to prevent therapists and participants
17 from knowing the group allocation because of the characteristics of moxibustion. To minimize the
18 bias, acupuncturists will receive professional training and strict quality control. In order to
19 homogenize the psychological effects, participants are informed that effects of the two
20 moxibustion techniques are uncertain. The words 'placebo' or 'control' will be avoided. Similar
21 strategies have been applied in previous trials^[62, 63]. Noncompliance of the control group is another
22 limitation of this pilot trial and may lead to a high drop-out rate. Each participant will be provided
23 with 150 RMB as financial compensation to improve compliance.
24

25 This study is the major sub-project focusing on stroke recovery, which is sponsored and funded
26 by the National Administration of Traditional Chinese Medicine of China. This protocol describes
27 the first pilot randomized controlled trial evaluating the feasibility to conduct a research to assess
28 the efficacy and safety of ginger-salt-indirect moxibustion on UUI after stroke. Results of this
29 preliminary study will provide essential information for the design of subsequent large-scale trials.
30 Further trials will focus on assessment of urodynamic parameters and evaluation of efficacy and
31 safety of moxibustion on UUI after stroke.
32

33 **Trial status**

34 The trial is currently in the recruitment phase.
35

36 **Author affiliations**

37 ¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital
38 Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China
39

40 ² Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital, China
41

42 **Contributors** LPW and HLL conceived this study and prepared the initial protocol. LLW drafted the manuscript
43 and participated in design of the study. GXS, YY, LZ, TZ participated in revising the protocol. LZ plans for the
44 statistical analysis. LPW and HLL made amendments of the trial protocol. All authors read and approved the final
45 manuscript.
46

47 **Funding** The trial is sponsored and funded by special project for the national clinical research bases construction
48 of traditional Chinese medicine belonging to the State Administration of Traditional Chinese Medicine of the
49 People's Republic of China, grant number: JD2X2012152.
50
51
52
53
54
55
56
57
58
59
60

Ethics approval Research ethics approval was attained from the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094).

Competing interests None.

Figure 1. Trial flowchart

Figure 2. Moxa cone moxibustion

Figure 3. Moxa box moxibustion

Figure 4. 72-hour frequency-volume chart

REFERENCES

1. Abrams P, Andersson K E, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn.* 2010; 29: 213-240.
2. Brittain K R, Peet S M, Potter J F, et al. Prevalence and management of urinary incontinence in stroke survivors. *Age Ageing.* 1999;28: 509-511.
3. Marinkovic S P, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. *J Urol.* 2001;165: 359-370.
4. Barrett J. Bladder and bowel problems after stroke. *Reviews in Clinical Gerontology.* 12: 253-267.
5. Williams M P, Srikanth V, Bird M, et al. Urinary symptoms and natural history of urinary continence after first-ever stroke--a longitudinal population-based study. *Age Ageing.* 2012; 41: 371-376.
6. Gelber D A, Good D C, Laven L J, et al. Causes of urinary incontinence after acute hemispheric stroke. *Stroke.* 1993;24: 378-382.
7. Santiagu S K, Arianayagam M, Wang A, et al. Urinary incontinence-pathophysiology and management outline. *Aust Fam Physician.* 2008; 37: 106-110.
8. Manack A, Motsko S P, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. *Neurourol Urodyn.* 2011;30: 395-401.
9. Nakayama H, Jorgensen H S, Pedersen P M, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. *Stroke.* 1997;28: 58-62.
10. Anderson C S, Jamrozik K D, Broadhurst R J, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke.* 1994;25: 1935-1944.
11. Patel M, Coshall C, Rudd A G, et al. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. *Stroke.* 2001; 32: 122-127.
12. Kolominsky-Rabas P L, Hilz M J, Neundoerfer B, et al. Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. *Neurourol Urodyn.* 2003; 22: 322-327.
13. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil.* 2005; 12: 66-76.
14. Gross J C. A comparison of the characteristics of incontinent and continent stroke patients in a rehabilitation program. *Rehabil Nurs.* 1998; 23: 132-140.
15. Hu T W, Wagner T H, Bentkover J D, et al. Costs of urinary incontinence and overactive bladder in

- the United States: a comparative study. *Urology*. 2004; 63: 461-465.
16. Levy R, Muller N. Urinary incontinence: economic burden and new choices in pharmaceutical treatment. *Adv Ther*. 2006; 23: 556-573.
 17. Wyman J F, Burgio K L, Newman D K. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. *Int J Clin Pract*. 2009; 63: 1177-1191.
 18. Godec C J. "Timed voiding"--a useful tool in the treatment of urinary incontinence. *Urology*. 1984; 23: 97-100.
 19. DK N: Conservative therapy for incontinence. In: *Female Urology: a Practical Clinical Guide*. Edited by Goldman, HB VS. New York: Humana Press; 2007: 63-79.
 20. Beetz R. Mild dehydration: a risk factor of urinary tract infection? *Eur J Clin Nutr*. 2003; 57: S52-S58.
 21. DK N: Lifestyle interventions. In: *Pelvic Floor Disorders*. Edited by Bourcier AP ME, P A. Philadelphia: Elsevier Saunders; 2004: 269-276.
 22. Koskimaki J, Hakama M, Huhtala H, et al. Association of smoking with lower urinary tract symptoms. *J Urol*. 1998; 159: 1580-1582.
 23. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)*. 1991; 3: 161-170.
 24. Richter H E, Creasman J M, Myers D L, et al. Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008; 19: 1653-1658.
 25. Milne J L. Behavioral therapies for overactive bladder: making sense of the evidence. *J Wound Ostomy Continence Nurs*. 2008; 35: 93-101, 102-103.
 26. Burgio K L. Behavioral treatment options for urinary incontinence. *Gastroenterology*. 2004; 126: S82-S89.
 27. Burgio K L. Current perspectives on management of urgency using bladder and behavioral training. *J Am Acad Nurse Pract*. 2004; 16: 4-7.
 28. Burgio K L, Goode P S, Locher J L, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. *JAMA*. 2002; 288: 2293-2299.
 29. Burgio K L, Locher J L, Goode P S, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA*. 1998; 280: 1995-2000.
 30. Wyman J F, Fantl J A, Mcclish D K, et al. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. *Am J Obstet Gynecol*. 1998; 179: 999-1007.
 31. Mattiasson A, Blaakaer J, Hoyer K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. *BJU Int*. 2003; 91: 54-60.
 32. Brown JH LN: Muscarinic receptor agonists and antagonists. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. Edited by Brunton L CBCB, 12th ed edn. New York: McGraw-Hill; 2011: 219-237.
 33. Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder. *BJU Int*. 2007; 100: 987-1006.
 34. Lam S, Hilar O. Pharmacologic management of overactive bladder. *Clin Interv Aging*. 2007; 2: 337-345.

35. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol.* 2008; 54: 740-763.
36. Chapple C R. Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology.* 2000; 55: 33-46, 50.
37. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. *Eur Urol.* 2005; 48: 5-26.
38. Chapple C R, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. *Eur Urol.* 2008; 54: 543-562.
39. George A. Management of Urinary Incontinence. *P&T.* 2012; 6: 345-361.
40. Thomas L H, Cross S, Barrett J, et al. Treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev.* 2008: D4462.
41. Thomas L H, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev.* 2005;3: D4462.
42. Dong H ZX: An overview of traditional Chinese medicine.Traditional Medicine in Asia. In: *New Delhi: World Health Organisation.* Edited by Chaudhary RR RU: Regional Office South -East Asia; 2002: 17-30.
43. H. Qinfeng W H L J. Bibliometric analysis of diseases spectrum of moxibustion therapy. *Journal of Acupuncture and Tuina Science.* 2012; 6: 334-342.
44. Deng H, Shen X. The Mechanism of Moxibustion: Ancient Theory and Modern Research. *Evid Based Complement Alternat Med.* 2013: 379291.
45. Liu H L, Wang L P. [Randomized controlled study on ginger-salt-partitioned moxibustion at shenque (CV 8) on urination disorders poststroke]. *Zhongguo Zhen Jiu.* 2006; 26: 621-624.
46. Sa J. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut Statist.* 2005: 287-291.
47. Cheng C W, Fu S F, Zhou Q H, et al. Extending the CONSORT Statement to moxibustion. *J Integr Med.* 2013; 11: 54-63.
48. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of days required to obtain reliable results. *Neurourol Urodyn.* 2003; 22: 92-96.
49. Lucas M G, Bosch R J, Burkhard F C, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur Urol.* 2012; 62: 1130-1142.
50. Ku J H, Jeong I G, Lim D J, et al. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. *Neurourol Urodyn.* 2004; 23: 331-335.
51. Wagner T H, Patrick D L, Bavendam T G, et al. Quality of life of persons with urinary incontinence: development of a new measure. *Urology.* 1996; 47: 67-71, 71-72.
52. Duffy L, Gajree S, Langhorne P, et al. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. *Stroke.* 2013; 44: 462-468.
53. Park J E, Lee S S, Lee M S, et al. Adverse events of moxibustion: a systematic review. *Complement Ther Med.* 2010; 18: 215-223.
54. Ernst E. Testing traditional cupping therapy. *J Pain.* 2009; 10: 555.
55. Yap T L, Cromwell D C, Emberton M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. *BJU Int.* 2007; 99: 9-16.
56. Brown J S, Mcnaughton K S, Wyman J F, et al. Measurement characteristics of a voiding diary for

- 1
2
3 use by men and women with overactive bladder. *Urology*. 2003; 61: 802-809.
- 4 57. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, *et al*: The 3-day bladder diary is a feasible,
5 reliable and valid tool to evaluate the lower urinary tract symptoms in women. *Neurourol Urodyn*.
6 2013; 22:1-5.
- 7
8 58. Bright E, Cotterill N, Drake M, *et al*: Developing and Validating the International Consultation on
9 Incontinence Questionnaire Bladder Diary. *Eur Urol* 2014;66:294-300.
- 10 59. Groutz A, Blaivas J G, Chaikin D C, *et al*. Noninvasive outcome measures of urinary incontinence
11 and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol*.
12 2000; 164: 698-701.
- 13 60. Tincello D G, Williams K S, Joshi M, *et al*. Urinary diaries: a comparison of data collected for
14 three days versus seven days. *Obstet Gynecol*. 2007; 109: 277-280.
- 15 61. Avery K N, Bosch J L, Gotoh M, *et al*. Questionnaires to assess urinary and anal incontinence:
16 review and recommendations. *J Urol*. 2007; 177: 39-49.
- 17 62. Linde K, Dincer F. How informed is consent in sham-controlled trials of acupuncture? *J Altern*
18 *Complement Med*. 2004; 10: 379-385.
- 19 63. Shi G X, Han L L, Liu L Y, *et al*. Acupuncture at local and distant points for tinnitus: study
20 protocol for a randomized controlled trial. *Trials*. 2012; 13: 224.
- 21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

LinPeng Wang¹, Lichen Wang¹, GuangXia Shi¹, Lin Zeng², Yi Yang¹, Tao Zhang¹, HuiLin Liu^{1*}

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University, Beijing, China

Correspondence to Dr. Hui-Lin Liu*; lhlxwy@aliyun.com

ABSTRACT

Introduction: Ginger-salt-indirect moxibustion is widely applied to treat urge urinary incontinence after stroke, which is a common complication in stroke survivors. Moxa cone moxibustion and moxa box moxibustion are main ~~techniques patterns~~ of ginger-salt-indirect moxibustion. Our previous study had shown that ginger-salt-indirect moxibustion using moxa cones was feasible and effective for urination disorders post-stroke. This pilot study aims to assess the feasibility of conducting research to evaluate the efficacy and safety of ginger-salt-indirect moxibustion for patients with post-stroke urge urinary incontinence.

Methods and analysis: This is a multicenter, prospective, single-blinded, pilot randomized controlled trial. 120 eligible patients will be randomly allocated to three groups. Treatment group A (n = 40) will receive moxa cone moxibustion and routine care; treatment group B (n = 40) will receive moxa box moxibustion and routine care; control group (n = 40) will only receive routine care for stroke recovery. The entire moxibustion treatment will consist of a total of 28 sessions during the course of 4 weeks. Primary outcome measure will be increase of mean volume per void assessed at week 4 from the baseline, based on the data of a 72-hour frequency-volume chart. Secondary outcome measures will include mean frequency of urination per day and quality of life assessments measured by completion of Incontinence Quality of Life Questionnaire and Barthel Index. All outcome measures will be assessed before the first moxibustion session (~~baseline~~), at 4 weeks and 16 weeks ~~from baselineafter the first moxibustion session~~. Adverse events in three groups will be recorded to assess safety of moxibustion.

Ethics and dissemination: Research ethics was approved by Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). Written informed consent will be ~~obtained achieved~~ from all participants. Study results will be published in peer-reviewed journals.

Trial Registration number: ISRCTN 44706974.

Strengths and limitations of this study

First pilot study to evaluate the feasibility of conducting research to assess the efficacy and safety of ginger-salt-indirect moxibustion as treatment for urge urinary incontinence after stroke
Multicentre, randomised controlled trial with pragmatic design
Interventions conducted by certified acupuncturists according to the STRICTOM and GCP.
Lack of blinding of acupuncturists and participants

INTRODUCTION

Urinary incontinence (UI) is defined as involuntary leakage of urine that causes hygienic or social problems by International Continence Society (ICS) ^[1]. Prevalence of UI after stroke varies from 32–79% at admission ^[2–4], 25% at hospital discharge and 15% after one year ^[4]. Urge urinary incontinence (UUI) is a common type of UI ^[5] after stroke. It urge urinary incontinence (UUI) after stroke is characterized by involuntary leakage of urine loss-accompanied or preceded by urgency ^[1], which arises from acute cerebral accident onset.

Results of previous review ^[6] suggested that there were three major causes of urinary incontinence after stroke: detrusor hyperreflexia caused by infarction; stroke-related cognitive or language deficits; bladder hyporeflexia with resultant overflow incontinence. UUI can be caused by detrusor overactivity due to the loss of inhibitory neurons after stroke ^[7]. Detrusor overactivity is characterized by involuntary detrusor contractions during the filling and storage phase ^[1, 7, 8]. When intra-detrusor pressure generated by abnormal detrusor contractions exceeds sphincter pressure, urinary incontinence occurs ^[7]. UI is a strong prognostic indicator for stroke recovery, which is associated with high rates of mortality ^[9, 10], disability ^[11] and increasing admission to institutional care ^[12]. Micturition disorders may result in urinary infection, nephritis, fungal dermatitis ^[13], and even bedsores. Typical symptoms, including frequent micturition, nocturia and urgency (~~compelling desire to void which is difficult to defer~~), could lead to impaired quality of life ^[14] and heavy economic burdens ^[15, 16].

Initial treatments for UUI after stroke recommended by ICS are behavioral therapy and pharmacotherapy ^[1]. Behavioral therapies, including healthy bladder habits and training techniques, aim at changing patients' lifestyle and at teaching patients to control urgency and enhance continence ability ^[17]. For habit modification, patients are guided to re-establish a healthy voiding schedule, eliminate bladder irritants from the diet, manage fluid intake and bowel regularity, control weight and give up smoking ^[18–24]. Training techniques consist of bladder training, urgency control techniques, pelvic muscle exercises, delayed voiding and multicomponent behavioral training ^[17]. Behavioral interventions are applied in the primary care setting, with or without pharmacotherapy ^[25–27]. Among these strategies, behavioral training and bladder training have the strongest efficacy evidence for the treatment of UUI ^[28–31]. Antimuscarinic drugs can reduce

urgency and improve bladder function ~~by with the mechanism of~~ controlling detrusor muscle overactivity through inhibition of M2 and M3 muscarinic bladder receptors on bladder^[32-34]. Several meta-analyses have shown that the most widely used antimuscarinic drugs have significant clinical benefits on UUI^[35-38]. ~~However, use Nevertheless, application~~ of antimuscarinic agents is ~~complicated influenced~~ by ~~dose dosing~~ convenience, drug contraindication and financial ~~concernsconsideration~~^[39]. A ~~Ceochrane~~ Cochrane systematic review^[40] concluded that no ~~rigorously~~ studies designed to manage urinary incontinence after stroke in secondary care had been ~~rigorously~~ conducted by far^[42]. ~~Although there is clinical guideline for the management of urinary incontinence after stroke~~^[1], ~~to date there is insufficient good quality evidence to support the current clinical practices~~^[41]. ~~Evidences of relevant trials were insufficient to guide clinical practices~~^[42]. More available therapies and well-designed studies are required to provide further evidences for management of UUI after stroke.

Moxibustion is a therapy using ignited materials (usually moxa) to heat selected points of the skin surface. This therapy is widely used ~~for as a treatment for cold syndrome and~~ chronic deficiency diseases^[42] and ~~is commonly indicated for UUI UUI was regarded as one of common indications~~^[43]. ~~The mechanism of Despite uncertain modern mechanisms, it is generally identified that~~ action of moxibustion ~~combines is produced by the meridian system combining with~~ thermal, radiation and pharmacological effects of the materials used, ~~acting on the meridian system~~^[44]. ~~Following the theory of Traditional Chinese Medicine (TCM), kidney qi regulates voiding function and ensures voluntary urination. Deficiency of kidney qi is known to be the primary pathogenesis of UI according to "ZhuBingYuanHouLun" (a famous ancient TCM literature). Ginger and salt are typically used on Shenque (CV8) acupoint to warm, tonify and nourish the kidney qi thereby controlling bladder and regulating voiding function.~~

~~In China, ginger-salt indirect moxibustion on CV8 (Shenque) is frequently applied to treat UUI after stroke.~~ Moxa cone moxibustion and moxa box moxibustion are primary techniques of ginger-salt-indirect moxibustion ~~commonly used~~ in clinical practices ~~in China~~. Moxa cone moxibustion involves a moxa cone burning directly on the ginger slice and providing thermal stimulus to the skin surface (see Figure 2). Moxa box moxibustion facilitates manipulations and reduces adverse reactions by using the device of moxa box with moxa sticks inside over the ginger slice (see Figure 3). Results of our previous study^[45] showed that ginger-salt-partitioned moxibustion with moxa cone could reduce mean daytime and nighttime voiding frequency in the treatment of urination disorders poststroke. ~~In addition Besides~~, we also observed that ginger-salt-indirect moxibustion with moxa cones could increase mean volume per void of UI after stroke in an unpublished study. ~~Our previous studies, together with results from an earlier Cochrane review~~^[40, 45] ~~suggest A recent cochrane review concluded that~~ ginger-salt-indirect moxibustion may be ~~worth investigating with a more rigorous study design effective for UI after stroke and worth further research~~^[48].

METHODS

Objectives

This pilot study is to evaluate the feasibility of a research to assess the efficacy and safety of ginger-salt-indirect moxibustion for the treatment of UUI after stroke.

Recruitment

This is a multicenter, single-blinded, pilot randomized controlled trial. The research consists of

three sequential parts (see Figure 1): a recruitment period before randomization, a treatment period of 4 weeks, and a follow-up period of 12 weeks. 120 eligible participants will be recruited from acupuncture wards of three hospitals according to the inclusion and exclusion criteria. During the first visit, potentially qualified patients will be provided with detailed information about this study, including the research objective, study procedure, potential benefits and risks. If a patient shows willingness to participate, they will be required to sign a written informed consent. This will be followed by baseline assessment and randomization~~will be conduct afterwards.~~

Design

Randomization and allocation concealment

The randomization scheme is provided by the Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical experts will use the block randomization method (block size of 6) of the SAS package (Version 9.1.3; SAS institute Inc., Cary, NC, USA) to form the random allocation sequence. Then computer-generated opaque sealed envelopes with serial number outside and group number inside will be produced. The envelopes will be kept in a secure locked drawer making it inaccessible to all study personnel. After baseline assessments, the envelopes will be opened sequentially by an independent researcher in front of the participants to ensure adequate concealment. Participants will be allocated to the three groups according to the group number printed inside the envelopes.

Blinding

Due to the feature of the moxibustion, it is difficult to make the therapists or participants blinded to the allocation. Data managers and statisticians will be blinded throughout the trial. During the intervention, therapists and data managers are requested not to communicate with each other about the allocation. Blinded telephone interviewers will collect the follow-up materials to evaluate long term effect of moxibustion at 16 weeks after the baseline first moxibustion session.

Participants

Sample size

Because this is a pilot study, a power calculation to determine sample size was not conducted. Sample size calculation will be was performed based on estimates of the number of participants we would expect to recruit within 24 months. We therefore plan to recruit five participants per month, according to our previous trial^[47]. A sample size of 40 per group and a total number of 120 will be included, which is larger than the minimum of 12 per group suggested for pilot studies^[46]. Outcomes of this pilot study will help calculate appropriate sample size for further randomized clinical trials.

Inclusion criteria

1. Male or female, aged 40- 75 years;
2. In-patients with UUI after stroke, according to the diagnosis criteria of the American Stroke Association (ASA) and the International Continence Society (ICS);
3. 4th to 48th week after stroke onset;
4. Normal consciousness, communication ability and recognition;
5. Written informed consent.

Exclusion criteria

1. UUI caused by spinal injury, multiple sclerosis or hyperplasia of prostate gland;
2. Chronic urinary retention or UI before stroke onset;
3. Stress urinary incontinence, mixed urinary incontinence and chronic urinary tract infection;

4. Insufficiency of heart, liver, kidney organs;
5. Participants in another clinical trial.

Discontinuation criteria

Reasons for discontinuation of treatment may include, but are not limited to, the following:

1. Participants' decision of discontinuation of treatment at any time for any reason;
2. Investigators' determination to discontinue the treatment for patient's safety and best interests at any time;
3. Non-compliance of participants with the study procedure (eg, study visits);
4. Concomitant therapy that could affect the study results during the trial;
5. Detection of protocol violations at any time.

Intervention

Ginger-Salt-Indirect Moxibustion is formulated on the basis of description in ancient literature and our ~~clinical experience~~^{previous research}^[47]. Moxibustion will be manipulated by certified acupuncturists with at least 20 years of clinical experience. All treatment details will be standardized between practitioners by guiding videos and relative trainings before the first acupuncture session. Interventions will be performed in accordance with the STRICTOM^[47] and good clinical practice guidelines (GCP).

Treatment group A

Participants in treatment group A will receive moxa cone moxibustion and routine care once a day for 4 weeks. The procedure of each session as it is used in normal practices is described as follows (see figure 2). Participants are asked to lie on a bed in a supine position and remove clothing to fully expose the navel in a temperature controlled room (25 to 30°C)~~room with 25 to 30°C temperature~~. A certain amount of salt is put on the navel to cover *Shenque* (CV8) acupoint and covered by a piece of fresh ginger slice (30mm in diameter and 4-5 mm in thickness). Then a moxa cone (pure wormwood fiber in material; 15 mm in diameter and 30 mm in length; Tongrentang Inc., China.) is placed on the fresh ginger slice and lit by the therapist. Once the moxa cone is burnt out, the therapist removes the whole moxa cone and replaces it with another one. The technique requires a sensation of heat but no painful burning sensation for participants. If participants feel pain or a burning sensation, the ginger slice with burning moxa cone will be removed immediately and reset after several minutes. Each session requires three units of moxa cone. The therapist is required to carefully observe the patient and whisk away the burning ash to avoid burning injury. This study is designed to evaluate moxibustion treatment as it is used in normal practice. The moxibustion group will also receive the usual care provided to the control group.

Treatment group B

Participants in treatment group B will receive moxa box moxibustion and routine care once a day for 4 weeks. The manipulations are generally similar to those in treatment group A. The only difference is that the double-holes moxa box (13 x 8 x 8.5 cm in volume) with two moxa sticks (pure wormwood fiber; 15 mm in diameter and 70 mm in length; Tongrentang Inc., China.) in the holes will be placed on the fresh ginger slice (see figure 3). The moxa sticks will be ignited from the bottom. If patients feel pain, the therapist will remove the lid with the moxa sticks for several minutes. Each session requires three units of moxa sticks.

Control group

According to pragmatic design, the control group will receive routine therapies for stroke recovery.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

These include control of blood pressure, inhibition of platelet aggregation, routine physiotherapy, occupational therapy and glucose control treatment. Participants in this group will be suggested to maintain their normal lifestyle, including diet, exercise and workload. Moreover, participants will be ~~encouraged suggested~~ to inform the researchers of any new treatments performed after entry into the trial.

Outcome measures

Primary outcome measures

Increase of mean volume per void at week 4 from baseline, based on 72-hour frequency-volume chart data.

Mean volume per void is one of the main quantitative indicators recorded in bladder dairies or frequency volume charts^[17, 31, 48-50]. It is ~~calculated defined~~ by dividing total volume of voluntary urination by total frequency of voluntary urination in 72 hours. Increase of mean volume per void objectively reflects improvement of bladder capacity and detrusor stability in the urine filling and storage period. In a previous study, we observed that mean volume per void increased in the ginger-salt-indirect moxibustion group, compared to the control group with a statistical difference. Consequently, we selected increase of mean volume per void at week 4 from the baseline as primary outcome. We will assess increase of mean volume per void at week 16 from the baseline to evaluate long-term efficacy as well.

Secondary outcome measures

1. The mean frequency of urination per day, including voluntary and incontinence urination.
2. Quality of life assessments measured by completion of the Incontinence Quality of Life Questionnaire (I-QOL)^[51] and the Barthel Index (BI)^[52].

The average frequency of urination per day is composed of mean frequency of voluntary and incontinent urination, which represents ~~the severity of reduction in~~ frequent micturition and urinary incontinence respectively. This is strongly linked to stability of bladder and detrusor. Questionnaires for quality of life assessment will be completed based on objective condition and subjective sensation of participants.

All outcome measures will be assessed before the baseline, at 4 weeks and 16 weeks from the baseline.

Adverse events

Adverse events (AEs) are defined as negative or unintended clinical manifestation following the treatments. Participants will be instructed to report any abnormal reactions to the clinical research team at any time. In addition, study investigators will collect information about abnormal reactions weekly by visiting the participants. All details of related and unexpected AEs, such as time of occurrence, degree and suspected causes, will be recorded on Case Report Forms (CRFs). The common AEs related to moxibustion Common adverse events include allergy, burn and infection are reported by a systematic review^[53]. AEs will be classified into 5 grades: Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Moderate (minimal, local or noninvasive intervention indicated); Severe (severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated); Very severe (life-threatening consequences; urgent intervention indicated); Death related to adverse events. Participants with mild and moderate AEs will receive symptomatic treatment and will be closely followed up by the research team. Severe AEs will be reported to the Research Ethics Committee within 48 hours. The Research Ethics Committee will

~~offer medical advice to the research team and determine whether the patient is eligible for further treatment. Adverse reactions should be reported by patients or caregivers and solved by the therapists.~~

Data management

Before recruitment, the whole research group, including therapists, data administrators and outcome assessors, will participate in a training seminar about research contents and data management. Baseline characteristics of participants will be recorded on CRFs by a research assistant. Data collection of urination and questionnaires will be conducted by a researcher who remains blinded to the group allocation at the baseline, 4 and 16 weeks after the baseline. Occupational caregivers will be trained to identify urinary incontinence and voluntary urination. Caregivers will collect urine of voluntary urination and measure it with a pot-shaped urine collector with scales. They will be trained to record accurate voiding time, voluntary urinary volume and urinary incontinence episodes on a 72-hour frequency-volume chart (see Figure 4). The record will be started at 8AM and last for 72 hours. If caregivers failed to collect urine in time, they will note voiding time and specific reasons on the chart. The blinded researcher will complete the urination section on CRFs according to the 72-hour frequency-volume charts handed in by caregivers.

Two independent researchers blinded to the group allocation will enter the data on Excel spreadsheet after the completion of the CRFs separately. Another independent researcher will compare the two data sets for check-up. If different data entry is discovered, data will be compared with the original CRFs to verify inconsistency. All modification will be marked on the CRFs. Research data will be gathered and saved abiding by the Data Protection Act 1998. Paper files will be kept in a locked filing cabinet and electronic documents will be stored in a password protected computer, with access restricted to the principal investigator. All research documents will be preserved for at least 5 years after publication.

Statistical analysis

Data analysis will be performed in a blinded pattern by statisticians of Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical analyses will be conducted on an intention-to-treat basis using the SPSS statistical package program (ver.18.0). Missing data will be replaced in accordance with the principle of the last observation carried forward. A P value < 0.05 ~~will be is~~ considered statistically significant with two-sided test. Baseline characteristics including gender, age and previous duration are described as n (%) for categorical data and mean \pm SD (standard deviation) for continuous data. To compare the differences among groups, we will perform analysis of variance (ANOVA) for normally distributed data, Kruskal-Wallis test for abnormally distributed data and chi-squared test for categorical data. Comparisons between two groups will be conducted using Bonferroni method of post hoc multiple comparisons.

Ethical considerations

This study adheres to the principles of the Declaration of Helsinki and has been approved by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). We will conduct the research in the following hospitals: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing Huguosi Hospital of Traditional Chinese Medicine and China Rehabilitation Research Center. Each participant will sign written informed consents voluntarily.

DISCUSSION

~~Exploration of UI dates back to the era of Yellow Emperor's Inner Canon in China. The term of UI after stroke was first recorded in "JingYueQuanShu", a Chinese ancient book by Zhang Jiebin. Ancient physicians began to realize that apoplexy was one of the causes of UI since then. In the theory of traditional Chinese medicine (TCM), kidney qi could regulate voiding function and ensure voluntary urination. Deficiency of kidney qi was known to be the primary pathogenesis referring to "ZhuBingYuanHouLun", a famous ancient TCM literature. Ginger and salt are able to warm and tonify the kidney Qi in TCM theory. Shenque (CV8) is applied as a principal acupoint for nourishing kidney Qi, which is only allowed to be used with moxibustion. Owing to the features of materials and usage, ginger-salt indirect moxibustion is likely to warm and nourish kidney Qi, thereby controlling bladder and regulating voiding function.~~

Placebo or sham control is encouraged in clinical trials to avoid bias^[54]. To our knowledge, no consensus has been established to recommend valid placebo or sham methods of moxibustion by far. Sham moxibustion is impractical to achieve blinding because of the common knowledge eognition of moxibustion in Chinese patients. Because of preference for moxibustion, incompliance of Chinese patients will make it difficult to use standard therapies as control treatment. Following pragmatic purpose, we set a usual care group as a blank control group, rather than a certain effective therapy or a sham device.

Concerning evaluation instruments, we selected 72-hour frequency-volume chart to record urination details and I-QOL together with Barthel Index to assess quality of life. The frequency volume chart and bladder diary is highly recommended in clinical trials by ICS^[1]. Frequency-volume charts record the time and volume of each voiding, as well as incontinence episodes. ICS suggested that frequency-volume charts should be recorded for at least 24 hours^[1]. ~~Recent literatures[48, 55-58] A considered that a~~ minimum of 72 hours wasis required to ensure reliability for diary parameters^[48, 55-58]. Thus, we will use a 72-hour frequency-volume chart to alleviate burdens for patients and improve compliance^[59, 60].

As for the assessment of quality of life, I-QOL is strongly recommended to assess the effect of urinary incontinence on patients' quality of life^[61]. ~~Previous A-recent~~ research^[51] has affirmed the reliability and validity of I-QOL as an incontinence-related QOL instrument in neurogenic UI patients. The items of I-QOL focus on three dimensions, namely social embarrassment, avoidance behaviors and psychosocial impacts, without physical mobility and self-care ability. Barthel Index is added to evaluate patients' activities of daily living, which is recognized as a valid and reliable outcome measurement for stroke survivors^[52].

One limitation of this pilot study is that we will be unable fail to prevent therapists and participants from knowing the group allocation because of the characteristics of moxibustion. To minimize the bias, acupuncturists will receive professional training and strict quality control. In order to homogenize the psychological effects, participants are informed that effects of the two moxibustion techniques are uncertain. The words 'placebo' or 'control' will be avoided. Similar strategies have been applied in previous trials^[62, 63]. Noncompliance of the control group is another limitation defeiency of this pilot trial and may lead to a high drop-out rate. Each participant will be provided with 150 RMB as financial compensation to improve compliance. We will solve this problem by providing participants with financial compensations and free moxibustion therapies after the completion of the entire trial.

This study is the major sub-project focusing on stroke recovery, which is sponsored and funded by the National Administration of Traditional Chinese Medicine of China. This protocol describes the first pilot randomized controlled trial evaluating the feasibility to conduct a research to assess the ~~efficacy curative effects~~ and safety of ginger-salt-indirect moxibustion on UUI after stroke. Results of this preliminary study will provide essential information for the design of subsequent large-scale trials. Further trials will focus on assessment of urodynamic parameters and evaluation of efficacy and safety of moxibustion on UUI after stroke.

Trial status

The trial is currently in the recruitment phase.

Author affiliations

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital, China

Contributors LPW and HLL conceived this study and prepared the initial protocol. LLW drafted the manuscript and participated in design of the study. GXS, YY, LZ, TZ participated in revising the protocol. LZ plans for the statistical analysis. LPW and HLL made amendments of the trial protocol. All authors read and approved the final manuscript.

Funding The trial is sponsored and funded by special project for the national clinical research bases construction of traditional Chinese medicine belonging to the State Administration of Traditional Chinese Medicine of the People's Republic of China, grant number: JD2X2012152.

Ethics approval Research ethics approval was attained from the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094).

Competing interests None.

Figure 1. Trial profile

Figure 2. Moxa cone moxibustion

Figure 3. Moxa box moxibustion

Figure 4. 72-hour frequency-volume chart

REFERENCES


1. Abrams P, Andersson K E, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn.* 2010; 29: 213-240.
2. Brittain K R, Peet S M, Potter J F, et al. Prevalence and management of urinary incontinence in stroke survivors. *Age Ageing.* 1999;28: 509-511.
3. Marinkovic S P, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. *J Urol.* 2001;165: 359-370.

4. Barrett J. Bladder and bowel problems after stroke. *Reviews in Clinical Gerontology*. 12: 253-267.
5. Williams M P, Srikanth V, Bird M, et al. Urinary symptoms and natural history of urinary continence after first-ever stroke--a longitudinal population-based study. *Age Ageing*. 2012; 41: 371-376.
6. Gelber D A, Good D C, Laven L J, et al. Causes of urinary incontinence after acute hemispheric stroke. *Stroke*. 1993;24: 378-382.
7. Santiago S K, Arianayagam M, Wang A, et al. Urinary incontinence-pathophysiology and management outline. *Aust Fam Physician*. 2008; 37: 106-110.
8. Manack A, Motsko S P, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. *Neurourol Urodyn*. 2011;30: 395-401.
9. Nakayama H, Jorgensen H S, Pedersen P M, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. *Stroke*. 1997;28: 58-62.
10. Anderson C S, Jamrozik K D, Broadhurst R J, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke*. 1994;25: 1935-1944.
11. Patel M, Coshall C, Rudd A G, et al. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. *Stroke*. 2001; 32: 122-127.
12. Kolominsky-Rabas P L, Hilz M J, Neundoerfer B, et al. Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. *Neurourol Urodyn*. 2003; 22: 322-327.
13. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil*. 2005; 12: 66-76.
14. Gross J C. A comparison of the characteristics of incontinent and continent stroke patients in a rehabilitation program. *Rehabil Nurs*. 1998; 23: 132-140.
15. Hu T W, Wagner T H, Bentkover J D, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology*. 2004; 63: 461-465.
16. Levy R, Muller N. Urinary incontinence: economic burden and new choices in pharmaceutical treatment. *Adv Ther*. 2006; 23: 556-573.
17. Wyman J F, Burgio K L, Newman D K. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. *Int J Clin Pract*. 2009; 63: 1177-1191.
18. Godec C J. "Timed voiding"--a useful tool in the treatment of urinary incontinence. *Urology*. 1984; 23: 97-100.
19. DK N: Conservative therapy for incontinence. In: *Female Urology: a Practical Clinical Guide*. Edited by Goldman, HB VS. New York: Humana Press; 2007: 63-79.
20. Beetz R. Mild dehydration: a risk factor of urinary tract infection? *Eur J Clin Nutr*. 2003; 57: S52-S58.
21. DK N: Lifestyle interventions. In: *Pelvic Floor Disorders*. Edited by Bourcier AP ME, P A. Philadelphia: Elsevier Saunders; 2004: 269-276.
22. Koskimaki J, Hakama M, Huhtala H, et al. Association of smoking with lower urinary tract symptoms. *J Urol*. 1998; 159: 1580-1582.
23. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)*. 1991; 3: 161-170.
24. Richter H E, Creasman J M, Myers D L, et al. Urodynamic characterization of obese women with

- 1
2
3 urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by
4 Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008; 19: 1653-1658.
- 5
6 25. Milne J L. Behavioral therapies for overactive bladder: making sense of the evidence. *J Wound*
7 *Ostomy Continence Nurs.* 2008; 35: 93-101, 102-103.
- 8
9 26. Burgio K L. Behavioral treatment options for urinary incontinence. *Gastroenterology.* 2004; 126:
10 S82-S89.
- 11
12 27. Burgio K L. Current perspectives on management of urgency using bladder and behavioral training.
13 *J Am Acad Nurse Pract.* 2004; 16: 4-7.
- 14
15 28. Burgio K L, Goode P S, Locher J L, et al. Behavioral training with and without biofeedback in the
16 treatment of urge incontinence in older women: a randomized controlled trial. *JAMA.* 2002; 288:
17 2293-2299.
- 18
19 29. Burgio K L, Locher J L, Goode P S, et al. Behavioral vs drug treatment for urge urinary
20 incontinence in older women: a randomized controlled trial. *JAMA.* 1998; 280: 1995-2000.
- 21
22 30. Wyman J F, Fantl J A, Mcclish D K, et al. Comparative efficacy of behavioral interventions in the
23 management of female urinary incontinence. Continence Program for Women Research Group.
24 *Am J Obstet Gynecol.* 1998; 179: 999-1007.
- 25
26 31. Mattiasson A, Blaakaer J, Hoyer K, et al. Simplified bladder training augments the effectiveness of
27 tolterodine in patients with an overactive bladder. *BJU Int.* 2003; 91: 54-60.
- 28
29 32. Brown JH LN: Muscarinic receptor agonists and antagonists. In: *Goodman & Gilman's The*
30 *Pharmacological Basis of Therapeutics.* Edited by Brunton L CBCB, 12th edn. New York:
31 McGraw-Hill;2011: 219-237.
- 32
33 33. Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder. *BJU Int.* 2007;
34 100: 987-1006.
- 35
36 34. Lam S, Hilar O. Pharmacologic management of overactive bladder. *Clin Interv Aging.* 2007; 2:
37 337-345.
- 38
39 35. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized
40 controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol.* 2008; 54: 740-763.
- 41
42 36. Chapple C R. Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology.*
43 2000; 55: 33-46, 50.
- 44
45 37. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
46 bladder: a systematic review and meta-analysis. *Eur Urol.* 2005; 48: 5-26.
- 47
48 38. Chapple C R, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
49 bladder: an update of a systematic review and meta-analysis. *Eur Urol.* 2008; 54: 543-562.
- 50
51 39. George A. Management of Urinary Incontinence. *P&T.* 2012; 6: 345-361.
- 52
53 40. Thomas L H, Cross S, Barrett J, et al. Treatment of urinary incontinence after stroke in adults.
54 *Cochrane Database Syst Rev.* 2008: D4462.
- 55
56 41. Thomas L H, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke
57 in adults. *Cochrane Database Syst Rev.* 2005;3: D4462.
- 58
59 42. Dong H ZX: An overview of traditional Chinese medicine. Traditional Medicine in Asia. In: *New*
60 *Delhi: World Health Organisation.* Edited by Chaudhary RR RU: Regional Office South -East
Asia; 2002: 17-30.
43. H. Qinfeng W H L J. Bibliometric analysis of diseases spectrum of moxibustion therapy. *Journal of*
Acupuncture and Tuina Science. 2012; 6: 334-342.
44. Deng H, Shen X. The Mechanism of Moxibustion: Ancient Theory and Modern Research. *Evid*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Based Complement Alternat Med.* 2013; 379291.
45. Liu H L, Wang L P. [Randomized controlled study on ginger-salt-partitioned moxibustion at shenque (CV 8) on urination disorders poststroke]. *Zhongguo Zhen Jiu.* 2006; 26: 621-624.
46. Sa J. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut Statist.* 2005: 287-291.
47. Cheng C W, Fu S F, Zhou Q H, et al. Extending the CONSORT Statement to moxibustion. *J Integr Med.* 2013; 11: 54-63.
48. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of days required to obtain reliable results. *Neurol Urodyn.* 2003; 22: 92-96.
49. Lucas M G, Bosch R J, Burkhard F C, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur Urol.* 2012; 62: 1130-1142.
50. Ku J H, Jeong I G, Lim D J, et al. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. *Neurol Urodyn.* 2004; 23: 331-335.
51. Wagner T H, Patrick D L, Bavendam T G, et al. Quality of life of persons with urinary incontinence: development of a new measure. *Urology.* 1996; 47: 67-71, 71-72.
52. Duffy L, Gajree S, Langhorne P, et al. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. *Stroke.* 2013; 44: 462-468.
53. Park J E, Lee S S, Lee M S, et al. Adverse events of moxibustion: a systematic review. *Complement Ther Med.* 2010; 18: 215-223.
54. Ernst E. Testing traditional cupping therapy. *J Pain.* 2009; 10: 555.
55. Yap T L, Cromwell D C, Emberton M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. *BJU Int.* 2007; 99: 9-16.
56. Brown J S, Mcnaughton K S, Wyman J F, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. *Urology.* 2003; 61: 802-809.
57. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, et al: The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. *Neurol Urodyn.* 2013; 22:1-5.
58. Bright E, Cotterill N, Drake M, et al: Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. *Eur Urol* 2014;66:294-300.
59. Groutz A, Blaivas J G, Chaikin D C, et al. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol.* 2000; 164: 698-701.
60. Tincello D G, Williams K S, Joshi M, et al. Urinary diaries: a comparison of data collected for three days versus seven days. *Obstet Gynecol.* 2007; 109: 277-280.
61. Avery K N, Bosch J L, Gotoh M, et al. Questionnaires to assess urinary and anal incontinence: review and recommendations. *J Urol.* 2007; 177: 39-49.
62. Linde K, Dincer F. How informed is consent in sham-controlled trials of acupuncture? *J Altern Complement Med.* 2004; 10: 379-385.
63. Shi G X, Han L L, Liu L Y, et al. Acupuncture at local and distant points for tinnitus: study protocol for a randomized controlled trial. *Trials.* 2012; 13: 224.

Figure 1 Trial profile



BMJ Open: first published as 10.1136/bmjopen-2014-006326 on 21 October 2014. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

Figure 2. Moxa cone moxibustion



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3. Moxa box moxibustion



view only

BMJ Open: first published as 10.1136/bmjopen-2014-006326 on 21 October 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

BMJ Open

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006326.R2
Article Type:	Protocol
Date Submitted by the Author:	19-Sep-2014
Complete List of Authors:	Wang, Linpeng; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Wang, Lichen; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Shi, Guangxia; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Zeng, Lin; Peking University Third Hospital, Research Center of Clinical Epidemiology Yang, Yi; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Zhang, Tao; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department Liu, Hiulin; Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Acupuncture and Moxibustion Department
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Urology, Neurology, Complementary medicine, Rehabilitation medicine
Keywords:	Urinary incontinences < UROLOGY, Neurology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

Linpeng Wang¹, Lichen Wang¹, Guangxia Shi¹, Lin Zeng², Yi Yang¹, Tao Zhang¹, Huilin Liu^{1*}

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University, Beijing, China

Correspondence to Dr. Huilin Liu*; lhlxwy@aliyun.com

ABSTRACT

Introduction: Ginger-salt-indirect moxibustion is widely applied to treat urge urinary incontinence after stroke, which is a common complication in stroke survivors. Moxa cone moxibustion and moxa box moxibustion are main techniques of ginger-salt-indirect moxibustion. Our previous study had shown that ginger-salt-indirect moxibustion using moxa cones was feasible and effective for urination disorders post-stroke. This pilot study aims to assess the feasibility of conducting research to evaluate the efficacy and safety of ginger-salt-indirect moxibustion for patients with post-stroke urge urinary incontinence.

Methods and analysis: This is a multicenter, prospective, single-blinded, pilot randomized controlled trial. 120 eligible patients will be randomly allocated to three groups. Treatment group A (n = 40) will receive moxa cone moxibustion and routine care; treatment group B (n = 40) will receive moxa box moxibustion and routine care; control group (n = 40) will only receive routine care for stroke recovery. The entire moxibustion treatment will consist of a total of 28 sessions during the course of 4 weeks. Primary outcome measure will be the increase of mean volume per void assessed at week 4 from the first moxibustion session (baseline). Secondary outcome measures will include mean frequency of urination per day and quality of life assessments measured by completion of Incontinence Quality of Life Questionnaire and Barthel Index. All outcome measures will be assessed at the baseline, 4 weeks and 16 weeks from baseline. Adverse events in three groups will be recorded to assess safety of moxibustion.

Ethics and dissemination: Research ethics was approved by Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). Written informed consent will be obtained from all participants. Study results will be published in peer-reviewed journals.

Trial Registration number: ISRCTN 44706974.

Strengths and limitations of this study

First pilot study to evaluate the feasibility of conducting research to assess the efficacy and safety of ginger-salt-indirect moxibustion as treatment for urge urinary incontinence after stroke

Multicentre, randomised controlled trial with pragmatic design

Interventions conducted by certified acupuncturists according to the STRICTOM and GCP

Lack of blinding of acupuncturists and participants

INTRODUCTION

Urinary incontinence (UI) is defined as involuntary leakage of urine that causes hygienic or social problems by International Continence Society (ICS)^[1]. Prevalence of UI after stroke varies from 32–79% at admission^[2-4], 25% at hospital discharge and 15% after one year^[4]. Urge urinary incontinence (UUI) is a common type of UI^[5] after stroke. It is characterized by involuntary leakage of urine accompanied or preceded by urgency^[1].

Results of previous review^[6] suggested that there were three major causes of urinary incontinence after stroke: detrusor hyperreflexia caused by infarction; stroke-related cognitive or language deficits; bladder hyporeflexia with resultant overflow incontinence. UUI can be caused by detrusor overactivity due to the loss of inhibitory neurons after stroke^[7]. Detrusor overactivity is characterized by involuntary detrusor contractions during the filling and storage phase^[1, 7, 8]. When intra-detrusor pressure generated by abnormal detrusor contractions exceeds sphincter pressure, urinary incontinence occurs^[7]. UI is a strong prognostic indicator for stroke recovery, which is associated with high rates of mortality^[9, 10], disability^[11] and increasing admission to institutional care^[12]. Micturition disorders may result in urinary infection, nephritis, fungal dermatitis^[13], and even bedsore. Typical symptoms, including frequent micturition, nocturia and urgency, could lead to impaired quality of life^[14] and heavy economic burdens^[15, 16].

Initial treatments for UUI after stroke recommended by ICS are behavioral therapy and pharmacotherapy^[1]. Behavioral therapies, including healthy bladder habits and training techniques, aim at changing patients' lifestyle and at teaching patients to control urgency and enhance continence ability^[17]. For habit modification, patients are guided to re-establish a healthy voiding schedule, eliminate bladder irritants from the diet, manage fluid intake and bowel regularity, control weight and give up smoking^[18-24]. Training techniques consist of bladder training, urgency control techniques, pelvic muscle exercises, delayed voiding and multicomponent behavioral training^[17]. Behavioral interventions are applied in the primary care setting, with or without pharmacotherapy^[25-27]. Among these strategies, behavioral training and bladder training have the strongest efficacy evidence for the treatment of UUI^[28-31]. Antimuscarinic drugs can reduce urgency and improve bladder function by controlling detrusor muscle overactivity through inhibition of M2 and M3 muscarinic bladder receptors^[32-34]. Several meta-analyses have shown that the most widely used antimuscarinic drugs have significant clinical benefits on UUI^[35-38].

1
2
3 However, use of antimuscarinic agents is complicated by dose convenience, drug contraindication
4 and financial concerns^[39]. A Cochrane systematic review^[40] concluded that no studies designed to
5 manage urinary incontinence after stroke in secondary care had been rigorously conducted so far.
6 Although there is clinical guideline for the management of urinary incontinence after stroke^[1], to
7 date there is insufficient good quality evidence to support current clinical practices^[41]. More
8 available therapies and well-designed studies are required to provide further evidences for
9 management of UUI after stroke.

10
11 Moxibustion is a therapy using ignited materials (usually moxa) to heat selected points of the
12 skin surface. This therapy is widely used for chronic deficiency diseases^[42] and is commonly
13 indicated for UUI^[43]. The mechanism of action of moxibustion combines thermal, radiation and
14 pharmacological effects of the materials used, acting on the meridian system^[44]. Following the
15 theory of Traditional Chinese Medicine (TCM), kidney *qi* regulates voiding function and ensures
16 voluntary urination. Deficiency of kidney *qi* is known to be the primary pathogenesis of UI
17 according to “ZhuBingYuanHouLun” (a famous ancient TCM literature). Ginger and salt are
18 typically used on *Shenque* (CV8) acupoint to warm, tonify and nourish the kidney *qi* thereby
19 controlling bladder and regulating voiding function.

20
21 Moxa cone moxibustion and moxa box moxibustion are primary techniques of
22 ginger-salt-indirect moxibustion, which are commonly used in clinical practices in China. Moxa
23 cone moxibustion involves a moxa cone burning directly on the ginger slice and providing thermal
24 stimulus to the skin surface (see Figure 2). Moxa box moxibustion facilitates manipulations and
25 reduces adverse reactions by using the device of moxa box with moxa sticks inside over the ginger
26 slice (see Figure 3). Results of our previous study^[45] showed that ginger-salt-partitioned
27 moxibustion with moxa cone could reduce mean daytime and nighttime voiding frequency in the
28 treatment of urination disorders poststroke. In addition, we also observed that ginger-salt-indirect
29 moxibustion with moxa cones could increase mean volume per void of UI after stroke in an
30 unpublished study. Our previous studies, together with results from an earlier Cochrane review^{[40,}
31 ^{45]} suggest ginger-salt-indirect moxibustion may be worth investigating with more rigorous study
32 design.

33 METHODS

34 Objectives

35 This pilot study is to evaluate the feasibility of a research to assess the efficacy and safety of
36 ginger-salt-indirect moxibustion for the treatment of UUI after stroke.

37 Recruitment

38 This is a multicenter, single-blinded, pilot randomized controlled trial. The research consists of
39 three sequential parts (see Figure 1): a recruitment period before randomization, a treatment period
40 of 4 weeks, and a follow-up period of 12 weeks. 120 eligible participants will be recruited from
41 acupuncture wards of three hospitals according to the inclusion and exclusion criteria. During the
42 first visit, potentially qualified patients will be provided with detailed information about this study,
43 including the research objective, study procedure, potential benefits and risks. If a patient shows
44 willingness to participate, they will be required to voluntarily sign a written informed consent.
45 This will be followed by baseline assessment and randomization.

46 Design

47 *Randomization and allocation concealment*

1
2
3 The randomization scheme is provided by the Research Center of Clinical Epidemiology
4 Affiliated to Peking University Third Hospital in China. Statistical experts will use the block
5 randomization method (block size of 6) of the SAS package (Version 9.1.3; SAS institute Inc.,
6 Cary, NC, USA) to form the random allocation sequence. Then computer-generated opaque sealed
7 envelopes with serial number outside and group number inside will be produced. The envelopes
8 will be kept in a secure locked drawer making it inaccessible to all study personnel. After baseline
9 assessments, the envelopes will be opened sequentially by an independent researcher in front of
10 the participants to ensure adequate concealment. Participants will be allocated to three groups
11 according to the group number printed inside the envelopes.
12

13 *Blinding*

14 Due to the feature of the moxibustion, it is difficult to make the therapists or participants blinded
15 to the allocation. Data managers and statisticians will be blinded throughout the trial. During the
16 intervention, therapists and data managers will be requested not to communicate with each other
17 about the allocation. Blinded telephone interviewers will collect the follow-up materials to
18 evaluate long term effect of moxibustion at 16 weeks after the baseline.
19

20 **Participants**

21 *Sample size*

22 Because this is a pilot study, a power calculation to determine sample size was not conducted.
23 Sample size calculation was performed based on estimates of the number of participants we would
24 expect to recruit within 24 months. We therefore plan to recruit five participants per month,
25 according to our previous trial. A sample size of 40 per group and a total number of 120 will be
26 included, which is larger than the minimum of 12 per group suggested for pilot studies^[46].
27 Outcomes of this pilot study will help calculate appropriate sample size for further randomized
28 clinical trials.
29

30 *Inclusion criteria*

- 31 1. Male or female, aged 40- 75 years;
- 32 2. In-patients with UUI after stroke, according to the diagnosis criteria of the American Stroke
33 Association (ASA) and the International Continence Society (ICS);
- 34 3. 4th to 48th week after stroke onset;
- 35 4. Normal consciousness, communication ability and recognition;
- 36 5. Written informed consent.

37 *Exclusion criteria*

- 38 1. UUI caused by spinal injury, multiple sclerosis or hyperplasia of prostate gland;
- 39 2. Chronic urinary retention or UI before stroke onset;
- 40 3. Stress urinary incontinence, mixed urinary incontinence and chronic urinary tract infection;
- 41 4. Insufficiency of heart, liver, kidney organs;
- 42 5. Participants in another clinical trial.

43 *Discontinuation criteria*

44 Reasons for discontinuation of treatment may include, but are not limited to, the following:

- 45 1. Participants' decision of discontinuation of treatment at any time for any reason;
- 46 2. Investigators' determination to discontinue the treatment for patient's safety and best interests at
47 any time;
- 48 3. Non-compliance of participants with the study procedure (eg, study visits);
- 49 4. Concomitant therapy that could affect the study results during the trial;

5. Detection of protocol violations at any time.

Intervention

Ginger-Salt-Indirect Moxibustion is formulated on the basis of description in ancient literature and our clinical experience. Moxibustion will be manipulated by certified acupuncturists with at least 20 years of clinical experience. All treatment details will be standardized between practitioners by guiding videos and relative trainings before the first acupuncture session. Interventions will be performed in accordance with the STRICTOM^[47] and good clinical practice guidelines (GCP).

Treatment group A

Participants in treatment group A will receive moxa cone moxibustion and routine care once a day for 4 weeks. The procedure of each session as it is used in normal practices is described as follows (see figure 2). Participants are asked to lie on a bed in a supine position and remove clothing to fully expose the navel in a temperature controlled room (25 to 30°C). A certain amount of salt is put on the navel to cover *Shenque* (CV8) acupoint and covered by a piece of fresh ginger slice (30mm in diameter and 4-5 mm in thickness). Then a moxa cone (pure wormwood fiber in material; 15 mm in diameter and 30 mm in length; Tongrentang Inc., China.) is placed on the fresh ginger slice and lit by the therapist. Once the moxa cone is burnt out, the therapist removes the whole moxa cone and replaces it with another one. The technique requires a sensation of heat but no painful burning sensation for participants. If participants feel pain or a burning sensation, the ginger slice with burning moxa cone will be removed immediately and reset after several minutes. Each session requires three units of moxa cone. The therapist is required to carefully observe the patient and whisk away the burning ash to avoid burning injury. Because this study is designed to evaluate moxibustion treatment as it is used in normal practice, the moxibustion group will also receive the usual care provided to the control group.

Treatment group B

Participants in treatment group B will receive moxa box moxibustion and routine care once a day for 4 weeks. The manipulations are generally similar to those in treatment group A. The only difference is that the double-holes moxa box (13 x 8 x 8.5 cm in volume) with two moxa sticks (pure wormwood fiber; 15 mm in diameter and 70 mm in length; Tongrentang Inc., China.) in the holes will be placed on the fresh ginger slice (see figure 3). The moxa sticks will be ignited from the bottom. If patients feel pain, the therapist will remove the lid with the moxa sticks for several minutes. Each session requires three units of moxa sticks.

Control group

According to pragmatic design, the control group will receive routine therapies for stroke recovery. These include control of blood pressure, inhibition of platelet aggregation, routine physiotherapy, occupational therapy and glucose control treatment. Participants in this group will be suggested to maintain their normal lifestyle, including diet, exercise and workload. Moreover, participants will be encouraged to inform the researchers of any new treatments performed after entry into the trial.

Outcome measures

Primary outcome measures

Increase of mean volume per void at week 4 from the baseline.

Mean volume per void is one of the main quantitative indicators recorded in bladder dairies or frequency volume charts^[17, 31, 48-50]. It is calculated by dividing total volume of voluntary urination by total frequency of voluntary urination, based on 72-hour frequency-volume chart data. Increase of mean volume per void objectively reflects improvement of bladder capacity and detrusor

1
2
3 stability in the urine filling and storage period. In a previous study, we observed that mean volume
4 per void increased in the ginger-salt-indirect moxibustion group, compared to the control group
5 with a statistical difference. Consequently, we selected increase of mean volume per void at week
6 4 from the baseline as primary outcome. We will assess increase of mean volume per void at week
7 16 from the baseline to evaluate long-term efficacy as well.

8 *Secondary outcome measures*

- 9
10
11 1. The mean frequency of urination per day, including voluntary and incontinence urination.
12 2. Quality of life assessments measured by completion of the Incontinence Quality of Life
13 Questionnaire (I-QOL)^[51] and the Barthel Index (BI)^[52].

14 The average frequency of urination per day is composed of mean frequency of voluntary and
15 incontinent urination, which represents the severity of frequent micturition and urinary
16 incontinence respectively. This is strongly linked to stability of bladder and detrusor.
17 Questionnaires for quality of life assessment will be completed based on objective condition and
18 subjective sensation of participants.

19 All outcome measures will be assessed before the baseline, at 4 weeks and 16 weeks from the
20 baseline.

21 *Adverse events*

22 Adverse events (AEs) are defined as negative or unintended clinical manifestations following the
23 treatment. Participants will be instructed to report any abnormal reactions to the clinical research
24 team at any time. In addition, study investigators will collect information about abnormal
25 reactions weekly by visiting the participants. All details of related and unexpected AEs, such as
26 time of occurrence, degree and suspected causes, will be recorded on Case Report Forms (CRFs).
27 The common AEs related to moxibustion include allergy, burn and infection^[53]. AEs will be
28 classified into 5 grades: Mild (asymptomatic or mild symptoms; clinical or diagnostic
29 observations only; intervention not indicated); Moderate (minimal, local or noninvasive
30 intervention indicated); Severe (severe or medically significant but not immediately
31 life-threatening; hospitalization or prolongation of hospitalization indicated); Very severe
32 (life-threatening consequences; urgent intervention indicated); Death related to adverse events.
33 Participants with mild and moderate AEs will receive symptomatic treatment and will be closely
34 followed up by the research team. Severe AEs will be reported to the Research Ethics Committee
35 within 48 hours. The Research Ethics Committee will offer medical advice to the research team
36 and determine whether the patient is eligible for further treatment.

37 **Data management**

38 Before recruitment, the whole research group, including therapists, data administrators and
39 outcome assessors, will participate in a training seminar about research contents and data
40 management. Baseline characteristics of participants will be recorded on CRFs by a research
41 assistant. Data collection of urination and questionnaires will be conducted by a researcher who
42 remains blinded to the group allocation at the baseline, 4 and 16 weeks from the baseline.
43 Occupational caregivers will be trained to identify urinary incontinence and voluntary urination.
44 Caregivers will collect urine of voluntary urination and measure it with a pot-shaped urine
45 collector with scales. They will be trained to record accurate voiding time, voluntary urinary
46 volume and urinary incontinence episodes on a 72-hour frequency-volume chart (see Figure 4).
47 The record will be started at 8AM and last for 72 hours. If caregivers failed to collect urine in time,
48 they will note voiding time and specific reasons on the chart. The blinded researcher will complete
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the urination section on CRFs according to the 72-hour frequency-volume charts handed in by
4 caregivers.

5
6 Two independent researchers blinded to the group allocation will enter the data on Excel
7 spreadsheet after the completion of the CRFs separately. Another independent researcher will
8 compare the two data sets for check-up. If different data entry is discovered, data will be
9 compared with the original CRFs to verify inconsistency. All modification will be marked on the
10 CRFs. Research data will be gathered and saved abiding by the Data Protection Act 1998. Paper
11 files will be kept in a locked filing cabinet. Electronic documents will be stored in a password
12 protected computer, with access restricted to the principal investigator. All research documents
13 will be preserved for at least 5 years after publication.

14 15 **Statistical analysis**

16
17 Data analysis will be performed in a blinded pattern by statisticians of Research Center of Clinical
18 Epidemiology Affiliated to Peking University Third Hospital in China. Statistical analyses will be
19 conducted on an intention-to-treat basis using the SPSS statistical package program (ver.18.0).
20 Missing data will be replaced in accordance with the principle of the last observation carried
21 forward. A P value < 0.05 will be considered statistically significant with two-sided test. Baseline
22 characteristics including gender, age and previous duration are described as n (%) for categorical
23 data and mean ± SD (standard deviation) for continuous data. To compare the differences among
24 groups, we will perform analysis of variance (ANOVA) for normally distributed data,
25 Kruskal-Wallis test for abnormally distributed data and chi-squared test for categorical data.
26 Comparisons between two groups will be conducted using Bonferroni method of post hoc multiple
27 comparisons.

28 29 **Ethical considerations**

30
31 This study adheres to the principles of the Declaration of Helsinki and has been approved by the
32 Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to
33 Capital Medical University (ref: 2013BL-094). We will conduct the research in the following
34 hospitals: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University,
35 Beijing Huguosi Hospital of Traditional Chinese Medicine and China Rehabilitation Research
36 Center. Each participant will sign written informed consents voluntarily.

37 38 **DISCUSSION**

39
40
41
42 Placebo or sham control is encouraged in clinical trials to avoid bias^[54]. To our knowledge, no
43 consensus has been established to recommend valid placebo or sham methods of moxibustion so
44 far. Sham moxibustion is unpractical to achieve blinding because of the common knowledge of
45 moxibustion in Chinese patients. Owing to the preference for moxibustion, incompliance of
46 Chinese patients will make it difficult to use standard therapies as control treatment. Following the
47 pragmatic purpose, we set a usual care group as a blank control group, rather than a certain
48 effective therapy or a sham device.

49
50
51
52 Concerning evaluation instruments, we selected 72-hour frequency-volume chart to record
53 urination details and I-QOL together with Barthel Index to assess quality of life. The frequency
54 volume chart and bladder diary is highly recommended in clinical trials by ICS^[1].
55 Frequency-volume charts record the time and volume of each voiding, as well as incontinence
56 episodes. ICS suggested that frequency-volume charts should be recorded for at least 24 hours^[1].
57 A minimum of 72 hours was required to ensure reliability for diary parameters^[48, 55-58]. Thus, we
58
59
60

1
2
3 will use a 72-hour frequency-volume chart to alleviate burdens for patients and improve
4 compliance^[59, 60].

5
6 As for the assessment of quality of life, I-QOL is strongly recommended to assess the effect of
7 urinary incontinence on patients' quality of life^[61]. Previous research^[51] has affirmed the reliability
8 and validity of I-QOL as an incontinence-related QOL instrument in neurogenic UI patients. The
9 items of I-QOL focus on three dimensions, namely social embarrassment, avoidance behavior and
10 psychosocial impact. Barthel Index is added to evaluate patients' activities of daily living, which is
11 recognized as a valid and reliable outcome measurement for stroke survivors^[52].

12
13 One limitation of this pilot study is that we will be unable to prevent therapists and participants
14 from knowing the group allocation because of the characteristics of moxibustion. To minimize the
15 bias, therapists will receive professional training and strict quality control. In order to homogenize
16 the psychological effects, participants are informed that effects of the two moxibustion techniques
17 are uncertain. The words 'placebo' or 'control' will be avoided. Similar strategies have been
18 applied in previous trials^[62, 63]. Noncompliance of the control group is another limitation of this
19 pilot trial. It may lead to a high drop-out rate. Participants will be provided with 150 RMB as
20 financial compensation to improve compliance.

21
22 This study is the major sub-project focusing on stroke recovery, which is sponsored and funded
23 by the National Administration of Traditional Chinese Medicine of China. This protocol describes
24 the first pilot randomized controlled trial evaluating the feasibility to conduct a research to assess
25 the efficacy and safety of ginger-salt-indirect moxibustion on UUI after stroke. Results of this
26 preliminary study will provide essential information for the design of subsequent large-scale trials.
27 Further trials will focus on assessment of urodynamic parameters and evaluation of efficacy and
28 safety of moxibustion on UUI after stroke.

29 30 31 32 33 **Trial status**

34 The trial is currently in the recruitment phase.

35 36 37 **Author affiliations**

38 ¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital
39 Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

40 ²Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital, China

41 42 43 **Acknowledgements**

44 We acknowledge State Administration of Traditional Chinese Medicine of China for agreeing to sponsor this study.
45 The authors also would like to thank Ines Janowicz for the English language editing and reviewers for the helpful
46 comments for this manuscript.

47
48
49 **Contributors** LPW and HLL conceived this study and prepared the initial protocol. LLW drafted the manuscript
50 and participated in design of the study. GXS, YY, LZ, TZ participated in revising the protocol. LZ plans for the
51 statistical analysis. LPW and HLL made amendments of the trial protocol. All authors read and approved the final
52 manuscript.

53
54
55 **Funding** The trial is sponsored and funded by special project for the national clinical research bases construction
56 of traditional Chinese medicine belonging to the State Administration of Traditional Chinese Medicine of the

People's Republic of China, grant number: JD2X2012152.

Ethics approval Research ethics approval was attained from the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094).

Competing interests None.

Figure 1. Trial flowchart

Figure 2. Moxa cone moxibustion

Figure 3. Moxa box moxibustion

Figure 4. 72-hour frequency-volume chart

REFERENCES

1. Abrams P, Andersson K E, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn.* 2010; 29: 213-240.
2. Brittain K R, Peet S M, Potter J F, et al. Prevalence and management of urinary incontinence in stroke survivors. *Age Ageing.* 1999;28: 509-511.
3. Marinkovic S P, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. *J Urol.* 2001;165: 359-370.
4. Barrett J. Bladder and bowel problems after stroke. *Reviews in Clinical Gerontology.* 12: 253-267.
5. Williams M P, Srikanth V, Bird M, et al. Urinary symptoms and natural history of urinary continence after first-ever stroke--a longitudinal population-based study. *Age Ageing.* 2012; 41: 371-376.
6. Gelber D A, Good D C, Laven L J, et al. Causes of urinary incontinence after acute hemispheric stroke. *Stroke.* 1993;24: 378-382.
7. Santiago S K, Arianayagam M, Wang A, et al. Urinary incontinence-pathophysiology and management outline. *Aust Fam Physician.* 2008; 37: 106-110.
8. Manack A, Motsko S P, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. *Neurourol Urodyn.* 2011;30: 395-401.
9. Nakayama H, Jorgensen H S, Pedersen P M, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. *Stroke.* 1997;28: 58-62.
10. Anderson C S, Jamrozik K D, Broadhurst R J, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke.* 1994;25: 1935-1944.
11. Patel M, Coshall C, Rudd A G, et al. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. *Stroke.* 2001; 32: 122-127.
12. Kolominsky-Rabas P L, Hilz M J, Neundoerfer B, et al. Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. *Neurourol Urodyn.* 2003; 22: 322-327.
13. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil.* 2005; 12: 66-76.
14. Gross J C. A comparison of the characteristics of incontinent and continent stroke patients in a

- rehabilitation program. *Rehabil Nurs*. 1998; 23: 132-140.
15. Hu T W, Wagner T H, Bentkover J D, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology*. 2004; 63: 461-465.
16. Levy R, Muller N. Urinary incontinence: economic burden and new choices in pharmaceutical treatment. *Adv Ther*. 2006; 23: 556-573.
17. Wyman J F, Burgio K L, Newman D K. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. *Int J Clin Pract*. 2009; 63: 1177-1191.
18. Godec C J. "Timed voiding"--a useful tool in the treatment of urinary incontinence. *Urology*. 1984; 23: 97-100.
19. DK N: Conservative therapy for incontinence. In: *Female Urology: a Practical Clinical Guide*. Edited by Goldman, HB VS. New York: Humana Press; 2007: 63-79.
20. Beetz R. Mild dehydration: a risk factor of urinary tract infection? *Eur J Clin Nutr*. 2003; 57: S52-S58.
21. DK N: Lifestyle interventions. In: *Pelvic Floor Disorders*. Edited by Bourcier AP ME, P A. Philadelphia: Elsevier Saunders; 2004: 269-276.
22. Koskimaki J, Hakama M, Huhtala H, et al. Association of smoking with lower urinary tract symptoms. *J Urol*. 1998; 159: 1580-1582.
23. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)*. 1991; 3: 161-170.
24. Richter H E, Creasman J M, Myers D L, et al. Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008; 19: 1653-1658.
25. Milne J L. Behavioral therapies for overactive bladder: making sense of the evidence. *J Wound Ostomy Continence Nurs*. 2008; 35: 93-101, 102-103.
26. Burgio K L. Behavioral treatment options for urinary incontinence. *Gastroenterology*. 2004; 126: S82-S89.
27. Burgio K L. Current perspectives on management of urgency using bladder and behavioral training. *J Am Acad Nurse Pract*. 2004; 16: 4-7.
28. Burgio K L, Goode P S, Locher J L, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. *JAMA*. 2002; 288: 2293-2299.
29. Burgio K L, Locher J L, Goode P S, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA*. 1998; 280: 1995-2000.
30. Wyman J F, Fantl J A, Mcclish D K, et al. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. *Am J Obstet Gynecol*. 1998; 179: 999-1007.
31. Mattiasson A, Blaakaer J, Hoye K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. *BJU Int*. 2003; 91: 54-60.
32. Brown JH LN: Muscarinic receptor agonists and antagonists. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. Edited by Brunton L CBCB, 12th ed edn. New York: McGraw-Hill; 2011: 219-237.
33. Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder. *BJU Int*. 2007; 100: 987-1006.

- 1
- 2
- 3 34. Lam S, Hilas O. Pharmacologic management of overactive bladder. *Clin Interv Aging*. 2007; 2:
- 4 337-345.
- 5
- 6 35. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized
- 7 controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol*. 2008; 54: 740-763.
- 8
- 9 36. Chapple C R. Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology*.
- 10 2000; 55: 33-46, 50.
- 11
- 12 37. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
- 13 bladder: a systematic review and meta-analysis. *Eur Urol*. 2005; 48: 5-26.
- 14
- 15 38. Chapple C R, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
- 16 bladder: an update of a systematic review and meta-analysis. *Eur Urol*. 2008; 54: 543-562.
- 17
- 18 39. George A. Management of Urinary Incontinence. *P&T*. 2012; 6: 345-361.
- 19
- 20 40. Thomas L H, Cross S, Barrett J, et al. Treatment of urinary incontinence after stroke in adults.
- 21 *Cochrane Database Syst Rev*. 2008: D4462.
- 22
- 23 41. Thomas L H, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke
- 24 in adults. *Cochrane Database Syst Rev*. 2005;3: D4462.
- 25
- 26 42. Dong H ZX: An overview of traditional Chinese medicine.Traditional Medicine in Asia. In: *New*
- 27 *Delhi: World Health Organisation*. Edited by Chaudhary RR RU: Regional Office South -East
- 28 Asia; 2002: 17-30.
- 29
- 30 43. H. Qinfeng W H L J. Bibliometric analysis of diseases spectrum of moxibustion therapy. *Journal of*
- 31 *Acupuncture and Tuina Science*. 2012; 6: 334-342.
- 32
- 33 44. Deng H, Shen X. The Mechanism of Moxibustion: Ancient Theory and Modern Research. *Evid*
- 34 *Based Complement Alternat Med*. 2013: 379291.
- 35
- 36 45. Liu H L, Wang L P. [Randomized controlled study on ginger-salt-partitioned moxibustion at
- 37 shenque (CV 8) on urination disorders poststroke]. *Zhongguo Zhen Jiu*. 2006; 26: 621-624.
- 38
- 39 46. Sa J. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut Statist*. 2005:
- 40 287-291.
- 41
- 42 47. Cheng C W, Fu S F, Zhou Q H, et al. Extending the CONSORT Statement to moxibustion. *J Integr*
- 43 *Med*. 2013; 11: 54-63.
- 44
- 45 48. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of
- 46 days required to obtain reliable results. *Neurourol Urodyn*. 2003; 22: 92-96.
- 47
- 48 49. Lucas M G, Bosch R J, Burkhard F C, et al. EAU guidelines on assessment and nonsurgical
- 49 management of urinary incontinence. *Eur Urol*. 2012; 62: 1130-1142.
- 50
- 51 50. Ku J H, Jeong I G, Lim D J, et al. Voiding diary for the evaluation of urinary incontinence and
- 52 lower urinary tract symptoms: prospective assessment of patient compliance and burden.
- 53 *Neurourol Urodyn*. 2004; 23: 331-335.
- 54
- 55 51. Wagner T H, Patrick D L, Bavendam T G, et al. Quality of life of persons with urinary
- 56 incontinence: development of a new measure. *Urology*. 1996; 47: 67-71, 71-72.
- 57
- 58 52. Duffy L, Gajree S, Langhorne P, et al. Reliability (inter-rater agreement) of the Barthel Index for
- 59 assessment of stroke survivors: systematic review and meta-analysis. *Stroke*. 2013; 44: 462-468.
- 60
- 53 53. Park J E, Lee S S, Lee M S, et al. Adverse events of moxibustion: a systematic review. *Complement*
- 54 *Ther Med*. 2010; 18: 215-223.
- 55
- 56 54. Ernst E. Testing traditional cupping therapy. *J Pain*. 2009; 10: 555.
- 57
- 58 55. Yap T L, Cromwell D C, Emberton M. A systematic review of the reliability of frequency-volume
- 59 charts in urological research and its implications for the optimum chart duration. *BJU Int*. 2007;
- 60

- 99: 9-16.
56. Brown J S, Mcnaughton K S, Wyman J F, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. *Urology*. 2003; 61: 802-809.
57. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, et al: The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. *Neurourol Urodyn*. 2013; 22:1-5.
58. Bright E, Cotterill N, Drake M, et al: Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. *Eur Urol* 2014;66:294-300.
59. Groutz A, Blaivas J G, Chaikin D C, et al. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol*. 2000; 164: 698-701.
60. Tincello D G, Williams K S, Joshi M, et al. Urinary diaries: a comparison of data collected for three days versus seven days. *Obstet Gynecol*. 2007; 109: 277-280.
61. Avery K N, Bosch J L, Gotoh M, et al. Questionnaires to assess urinary and anal incontinence: review and recommendations. *J Urol*. 2007; 177: 39-49.
62. Linde K, Dincer F. How informed is consent in sham-controlled trials of acupuncture? *J Altern Complement Med*. 2004; 10: 379-385.
63. Shi G X, Han L L, Liu L Y, et al. Acupuncture at local and distant points for tinnitus: study protocol for a randomized controlled trial. *Trials*. 2012; 13: 224.

Efficacy and safety of Ginger-Salt-Indirect Moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicenter randomized controlled trial

LinPeng Wang¹, Lichen Wang¹, GuangXia Shi¹, Lin Zeng², Yi Yang¹, Tao Zhang¹, HuiLin Liu^{1*}

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

² Research Center of Clinical Epidemiology Affiliated to Peking University, Beijing, China

Correspondence to Dr. Hui-Lin Liu*; lhlxwy@aliyun.com

ABSTRACT

Introduction: Ginger-salt-indirect moxibustion is widely applied to treat urge urinary incontinence after stroke, which is a common complication in stroke survivors. Moxa cone moxibustion and moxa box moxibustion are main ~~techniques patterns~~ of ginger-salt-indirect moxibustion. Our previous study had shown that ginger-salt-indirect moxibustion using moxa cones was feasible and effective for urination disorders post-stroke. This pilot study aims to assess the feasibility of conducting research to evaluate the efficacy and safety of ginger-salt-indirect moxibustion for patients with post-stroke urge urinary incontinence.

Methods and analysis: This is a multicenter, prospective, single-blinded, pilot randomized controlled trial. 120 eligible patients will be randomly allocated to three groups. Treatment group A (n = 40) will receive moxa cone moxibustion and routine care; treatment group B (n = 40) will receive moxa box moxibustion and routine care; control group (n = 40) will only receive routine care for stroke recovery. The entire moxibustion treatment will consist of a total of 28 sessions during the course of 4 weeks. Primary outcome measure will be increase of mean volume per void assessed at week 4 from the baseline, based on the data of a 72-hour frequency-volume chart. Secondary outcome measures will include mean frequency of urination per day and quality of life assessments measured by completion of Incontinence Quality of Life Questionnaire and Barthel Index. All outcome measures will be assessed before the first moxibustion session (~~baseline~~), at 4 weeks and 16 weeks ~~from baselineafter the first moxibustion session~~. Adverse events in three groups will be recorded to assess safety of moxibustion.

Ethics and dissemination: Research ethics was approved by Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). Written informed consent will be ~~obtained achieved~~ from all participants. Study results will be published in peer-reviewed journals.

Trial Registration number: ISRCTN 44706974.

Strengths and limitations of this study

First pilot study to evaluate the feasibility of conducting research to assess the efficacy and safety of ginger-salt-indirect moxibustion as treatment for urge urinary incontinence after stroke
Multicentre, randomised controlled trial with pragmatic design
Interventions conducted by certified acupuncturists according to the STRICTOM and GCP.
Lack of blinding of acupuncturists and participants

INTRODUCTION

Urinary incontinence (UI) is defined as involuntary leakage of urine that causes hygienic or social problems by International Continence Society (ICS) [1]. Prevalence of UI after stroke varies from 32–79% at admission [2–4], 25% at hospital discharge and 15% after one year [4]. Urge urinary incontinence (UUI) is a common type of UI [5] after stroke. It urge urinary incontinence (UUI) after stroke is characterized by involuntary leakage of urine loss-accompanied or preceded by urgency [1], which arises from acute cerebral accident onset.

Results of previous review [6] suggested that there were three major causes of urinary incontinence after stroke: detrusor hyperreflexia caused by infarction; stroke-related cognitive or language deficits; bladder hyporeflexia with resultant overflow incontinence. UUI can be caused by detrusor overactivity due to the loss of inhibitory neurons after stroke [7]. Detrusor overactivity is characterized by involuntary detrusor contractions during the filling and storage phase [1, 7, 8]. When intra-detrusor pressure generated by abnormal detrusor contractions exceeds sphincter pressure, urinary incontinence occurs [7]. UI is a strong prognostic indicator for stroke recovery, which is associated with high rates of mortality [9, 10], disability [11] and increasing admission to institutional care [12]. Micturition disorders may result in urinary infection, nephritis, fungal dermatitis [13], and even bedsores. Typical symptoms, including frequent micturition, nocturia and urgency (~~compelling desire to void which is difficult to defer~~), could lead to impaired quality of life [14] and heavy economic burdens [15, 16].

Initial treatments for UUI after stroke recommended by ICS are behavioral therapy and pharmacotherapy [1]. Behavioral therapies, including healthy bladder habits and training techniques, aim at changing patients' lifestyle and at teaching patients to control urgency and enhance continence ability [17]. For habit modification, patients are guided to re-establish a healthy voiding schedule, eliminate bladder irritants from the diet, manage fluid intake and bowel regularity, control weight and give up smoking [18–24]. Training techniques consist of bladder training, urgency control techniques, pelvic muscle exercises, delayed voiding and multicomponent behavioral training [17]. Behavioral interventions are applied in the primary care setting, with or without pharmacotherapy [25–27]. Among these strategies, behavioral training and bladder training have the strongest efficacy evidence for the treatment of UUI [28–31]. Antimuscarinic drugs can reduce

urgency and improve bladder function ~~by with the mechanism of~~ controlling detrusor muscle overactivity through inhibition of M2 and M3 muscarinic bladder receptors on bladder^[32-34]. Several meta-analyses have shown that the most widely used antimuscarinic drugs have significant clinical benefits on UUI^[35-38]. ~~However, use Nevertheless, application~~ of antimuscarinic agents is ~~complicated influenced~~ by ~~dose dosing~~ convenience, drug contraindication and financial ~~concernsconsideration~~^[39]. A ~~Ceochrane~~ Cochrane systematic review^[40] concluded that no ~~rigorously~~ studies designed to manage urinary incontinence after stroke in secondary care had been ~~rigorously~~ conducted by far^[42]. ~~Although there is clinical guideline for the management of urinary incontinence after stroke~~^[1], ~~to date there is insufficient good quality evidence to support the current clinical practices~~^[41]. ~~Evidences of relevant trials were insufficient to guide clinical practices~~^[42]. More available therapies and well-designed studies are required to provide further evidences for management of UUI after stroke.

Moxibustion is a therapy using ignited materials (usually moxa) to heat selected points of the skin surface. This therapy is widely used ~~for as a treatment for cold syndrome and~~ chronic deficiency diseases^[42] and ~~is commonly indicated for UUI UUI was regarded as one of common indications~~^[43]. ~~The mechanism of Despite uncertain modern mechanisms, it is generally identified that~~ action of moxibustion ~~combines is produced by the meridian system combining with~~ thermal, radiation and pharmacological effects of the materials used, ~~acting on the meridian system~~^[44]. ~~Following the theory of Traditional Chinese Medicine (TCM), kidney qi regulates voiding function and ensures voluntary urination. Deficiency of kidney qi is known to be the primary pathogenesis of UI according to "ZhuBingYuanHouLun" (a famous ancient TCM literature). Ginger and salt are typically used on Shenque (CV8) acupoint to warm, tonify and nourish the kidney qi thereby controlling bladder and regulating voiding function.~~

~~In China, ginger-salt indirect moxibustion on CV8 (Shenque) is frequently applied to treat UUI after stroke.~~ Moxa cone moxibustion and moxa box moxibustion are primary techniques of ginger-salt-indirect moxibustion ~~commonly used~~ in clinical practices ~~in China~~. Moxa cone moxibustion involves a moxa cone burning directly on the ginger slice and providing thermal stimulus to the skin surface (see Figure 2). Moxa box moxibustion facilitates manipulations and reduces adverse reactions by using the device of moxa box with moxa sticks inside over the ginger slice (see Figure 3). Results of our previous study^[45] showed that ginger-salt-partitioned moxibustion with moxa cone could reduce mean daytime and nighttime voiding frequency in the treatment of urination disorders poststroke. ~~In addition Besides~~, we also observed that ginger-salt-indirect moxibustion with moxa cones could increase mean volume per void of UI after stroke in an unpublished study. ~~Our previous studies, together with results from an earlier Cochrane review~~^[40, 45] ~~suggest A recent cochrane review concluded that~~ ginger-salt-indirect moxibustion may be ~~worth investigating with a more rigorous study design effective for UI after stroke and worth further research~~^[48].

METHODS

Objectives

This pilot study is to evaluate the feasibility of a research to assess the efficacy and safety of ginger-salt-indirect moxibustion for the treatment of UUI after stroke.

Recruitment

This is a multicenter, single-blinded, pilot randomized controlled trial. The research consists of

three sequential parts (see Figure 1): a recruitment period before randomization, a treatment period of 4 weeks, and a follow-up period of 12 weeks. 120 eligible participants will be recruited from acupuncture wards of three hospitals according to the inclusion and exclusion criteria. During the first visit, potentially qualified patients will be provided with detailed information about this study, including the research objective, study procedure, potential benefits and risks. If a patient shows willingness to participate, they will be required to sign a written informed consent. This will be followed by baseline assessment and randomization~~will be conduct afterwards.~~

Design

Randomization and allocation concealment

The randomization scheme is provided by the Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical experts will use the block randomization method (block size of 6) of the SAS package (Version 9.1.3; SAS institute Inc., Cary, NC, USA) to form the random allocation sequence. Then computer-generated opaque sealed envelopes with serial number outside and group number inside will be produced. The envelopes will be kept in a secure locked drawer making it inaccessible to all study personnel. After baseline assessments, the envelopes will be opened sequentially by an independent researcher in front of the participants to ensure adequate concealment. Participants will be allocated to the three groups according to the group number printed inside the envelopes.

Blinding

Due to the feature of the moxibustion, it is difficult to make the therapists or participants blinded to the allocation. Data managers and statisticians will be blinded throughout the trial. During the intervention, therapists and data managers are requested not to communicate with each other about the allocation. Blinded telephone interviewers will collect the follow-up materials to evaluate long term effect of moxibustion at 16 weeks after the baseline first moxibustion session.

Participants

Sample size

Because this is a pilot study, a power calculation to determine sample size was not conducted. Sample size calculation will be was performed based on estimates of the number of participants we would expect to recruit within 24 months. We therefore plan to recruit five participants per month, according to our previous trial^[47]. A sample size of 40 per group and a total number of 120 will be included, which is larger than the minimum of 12 per group suggested for pilot studies^[46]. Outcomes of this pilot study will help calculate appropriate sample size for further randomized clinical trials.

Inclusion criteria

1. Male or female, aged 40- 75 years;
2. In-patients with UUI after stroke, according to the diagnosis criteria of the American Stroke Association (ASA) and the International Continence Society (ICS);
3. 4th to 48th week after stroke onset;
4. Normal consciousness, communication ability and recognition;
5. Written informed consent.

Exclusion criteria

1. UUI caused by spinal injury, multiple sclerosis or hyperplasia of prostate gland;
2. Chronic urinary retention or UI before stroke onset;
3. Stress urinary incontinence, mixed urinary incontinence and chronic urinary tract infection;

4. Insufficiency of heart, liver, kidney organs;
5. Participants in another clinical trial.

Discontinuation criteria

Reasons for discontinuation of treatment may include, but are not limited to, the following:

1. Participants' decision of discontinuation of treatment at any time for any reason;
2. Investigators' determination to discontinue the treatment for patient's safety and best interests at any time;
3. Non-compliance of participants with the study procedure (eg, study visits);
4. Concomitant therapy that could affect the study results during the trial;
5. Detection of protocol violations at any time.

Intervention

Ginger-Salt-Indirect Moxibustion is formulated on the basis of description in ancient literature and our ~~clinical experience~~^{previous research}^[47]. Moxibustion will be manipulated by certified acupuncturists with at least 20 years of clinical experience. All treatment details will be standardized between practitioners by guiding videos and relative trainings before the first acupuncture session. Interventions will be performed in accordance with the STRICTOM^[47] and good clinical practice guidelines (GCP).

Treatment group A

Participants in treatment group A will receive moxa cone moxibustion and routine care once a day for 4 weeks. The procedure of each session as it is used in normal practices is described as follows (see figure 2). Participants are asked to lie on a bed in a supine position and remove clothing to fully expose the navel in a ~~temperature controlled room (25 to 30°C)~~^{room with 25 to 30°C temperature}. A certain amount of salt is put on the navel to cover *Shenque* (CV8) acupoint and covered by a piece of fresh ginger slice (30mm in diameter and 4-5 mm in thickness). Then a moxa cone (pure wormwood fiber in material; 15 mm in diameter and 30 mm in length; Tongrentang Inc., China.) is placed on the fresh ginger slice and lit by the therapist. Once the moxa cone is burnt out, the therapist removes the whole moxa cone and replaces it with another one. The technique requires a sensation of heat but no painful burning sensation for participants. If participants feel pain or a burning sensation, the ginger slice with burning moxa cone will be removed immediately and reset after several minutes. Each session requires three units of moxa cone. The therapist is required to carefully observe the patient and whisk away the burning ash to avoid burning injury. This study is designed to evaluate moxibustion treatment as it is used in normal practice. The moxibustion group will also receive the usual care provided to the control group.

Treatment group B

Participants in treatment group B will receive moxa box moxibustion and routine care once a day for 4 weeks. The manipulations are generally similar to those in treatment group A. The only difference is that the double-holes moxa box (13 x 8 x 8.5 cm in volume) with two moxa sticks (pure wormwood fiber; 15 mm in diameter and 70 mm in length; Tongrentang Inc., China.) in the holes will be placed on the fresh ginger slice (see figure 3). The moxa sticks will be ignited from the bottom. If patients feel pain, the therapist will remove the lid with the moxa sticks for several minutes. Each session requires three units of moxa sticks.

Control group

According to pragmatic design, the control group will receive routine therapies for stroke recovery.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

These include control of blood pressure, inhibition of platelet aggregation, routine physiotherapy, occupational therapy and glucose control treatment. Participants in this group will be suggested to maintain their normal lifestyle, including diet, exercise and workload. Moreover, participants will be ~~encouraged suggested~~ to inform the researchers of any new treatments performed after entry into the trial.

Outcome measures

Primary outcome measures

Increase of mean volume per void at week 4 from baseline, based on 72-hour frequency-volume chart data.

Mean volume per void is one of the main quantitative indicators recorded in bladder dairies or frequency volume charts^[17, 31, 48-50]. It is ~~calculated defined~~ by dividing total volume of voluntary urination by total frequency of voluntary urination in 72 hours. Increase of mean volume per void objectively reflects improvement of bladder capacity and detrusor stability in the urine filling and storage period. In a previous study, we observed that mean volume per void increased in the ginger-salt-indirect moxibustion group, compared to the control group with a statistical difference. Consequently, we selected increase of mean volume per void at week 4 from the baseline as primary outcome. We will assess increase of mean volume per void at week 16 from the baseline to evaluate long-term efficacy as well.

Secondary outcome measures

1. The mean frequency of urination per day, including voluntary and incontinence urination.
2. Quality of life assessments measured by completion of the Incontinence Quality of Life Questionnaire (I-QOL)^[51] and the Barthel Index (BI)^[52].

The average frequency of urination per day is composed of mean frequency of voluntary and incontinent urination, which represents ~~the severity of reduction in~~ frequent micturition and urinary incontinence respectively. This is strongly linked to stability of bladder and detrusor. Questionnaires for quality of life assessment will be completed based on objective condition and subjective sensation of participants.

All outcome measures will be assessed before the baseline, at 4 weeks and 16 weeks from the baseline.

Adverse events

Adverse events (AEs) are defined as negative or unintended clinical manifestation following the treatments. Participants will be instructed to report any abnormal reactions to the clinical research team at any time. In addition, study investigators will collect information about abnormal reactions weekly by visiting the participants. All details of related and unexpected AEs, such as time of occurrence, degree and suspected causes, will be recorded on Case Report Forms (CRFs). The common AEs related to moxibustion Common adverse events include allergy, burn and infection are reported by a systematic review^[53]. AEs will be classified into 5 grades: Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Moderate (minimal, local or noninvasive intervention indicated); Severe (severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated); Very severe (life-threatening consequences; urgent intervention indicated); Death related to adverse events. Participants with mild and moderate AEs will receive symptomatic treatment and will be closely followed up by the research team. Severe AEs will be reported to the Research Ethics Committee within 48 hours. The Research Ethics Committee will

~~offer medical advice to the research team and determine whether the patient is eligible for further treatment. Adverse reactions should be reported by patients or caregivers and solved by the therapists.~~

Data management

Before recruitment, the whole research group, including therapists, data administrators and outcome assessors, will participate in a training seminar about research contents and data management. Baseline characteristics of participants will be recorded on CRFs by a research assistant. Data collection of urination and questionnaires will be conducted by a researcher who remains blinded to the group allocation at the baseline, 4 and 16 weeks after the baseline. Occupational caregivers will be trained to identify urinary incontinence and voluntary urination. Caregivers will collect urine of voluntary urination and measure it with a pot-shaped urine collector with scales. They will be trained to record accurate voiding time, voluntary urinary volume and urinary incontinence episodes on a 72-hour frequency-volume chart (see Figure 4). The record will be started at 8AM and last for 72 hours. If caregivers failed to collect urine in time, they will note voiding time and specific reasons on the chart. The blinded researcher will complete the urination section on CRFs according to the 72-hour frequency-volume charts handed in by caregivers.

Two independent researchers blinded to the group allocation will enter the data on Excel spreadsheet after the completion of the CRFs separately. Another independent researcher will compare the two data sets for check-up. If different data entry is discovered, data will be compared with the original CRFs to verify inconsistency. All modification will be marked on the CRFs. Research data will be gathered and saved abiding by the Data Protection Act 1998. Paper files will be kept in a locked filing cabinet and electronic documents will be stored in a password protected computer, with access restricted to the principal investigator. All research documents will be preserved for at least 5 years after publication.

Statistical analysis

Data analysis will be performed in a blinded pattern by statisticians of Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital in China. Statistical analyses will be conducted on an intention-to-treat basis using the SPSS statistical package program (ver.18.0). Missing data will be replaced in accordance with the principle of the last observation carried forward. A P value < 0.05 ~~will be is~~ considered statistically significant with two-sided test. Baseline characteristics including gender, age and previous duration are described as n (%) for categorical data and mean ± SD (standard deviation) for continuous data. To compare the differences among groups, we will perform analysis of variance (ANOVA) for normally distributed data, Kruskal-Wallis test for abnormally distributed data and chi-squared test for categorical data. Comparisons between two groups will be conducted using Bonferroni method of post hoc multiple comparisons.

Ethical considerations

This study adheres to the principles of the Declaration of Helsinki and has been approved by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094). We will conduct the research in the following hospitals: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing Huguosi Hospital of Traditional Chinese Medicine and China Rehabilitation Research Center. Each participant will sign written informed consents voluntarily.

DISCUSSION

~~Exploration of UI dates back to the era of Yellow Emperor's Inner Canon in China. The term of UI after stroke was first recorded in "JingYueQuanShu", a Chinese ancient book by Zhang Jiebin. Ancient physicians began to realize that apoplexy was one of the causes of UI since then. In the theory of traditional Chinese medicine (TCM), kidney qi could regulate voiding function and ensure voluntary urination. Deficiency of kidney qi was known to be the primary pathogenesis referring to "ZhuBingYuanHouLun", a famous ancient TCM literature. Ginger and salt are able to warm and tonify the kidney Qi in TCM theory. Shenque (CV8) is applied as a principal acupoint for nourishing kidney Qi, which is only allowed to be used with moxibustion. Owing to the features of materials and usage, ginger-salt indirect moxibustion is likely to warm and nourish kidney Qi, thereby controlling bladder and regulating voiding function.~~

Placebo or sham control is encouraged in clinical trials to avoid bias^[54]. To our knowledge, no consensus has been established to recommend valid placebo or sham methods of moxibustion by far. Sham moxibustion is impractical to achieve blinding because of the common knowledge eognition of moxibustion in Chinese patients. Because of preference for moxibustion, incompliance of Chinese patients will make it difficult to use standard therapies as control treatment. Following pragmatic purpose, we set a usual care group as a blank control group, rather than a certain effective therapy or a sham device.

Concerning evaluation instruments, we selected 72-hour frequency-volume chart to record urination details and I-QOL together with Barthel Index to assess quality of life. The frequency volume chart and bladder diary is highly recommended in clinical trials by ICS^[1]. Frequency-volume charts record the time and volume of each voiding, as well as incontinence episodes. ICS suggested that frequency-volume charts should be recorded for at least 24 hours^[1]. ~~Recent literatures[48, 55-58] A considered that a~~ minimum of 72 hours wasis required to ensure reliability for diary parameters^[48, 55-58]. Thus, we will use a 72-hour frequency-volume chart to alleviate burdens for patients and improve compliance^[59, 60].

As for the assessment of quality of life, I-QOL is strongly recommended to assess the effect of urinary incontinence on patients' quality of life^[61]. ~~Previous A-recent~~ research^[51] has affirmed the reliability and validity of I-QOL as an incontinence-related QOL instrument in neurogenic UI patients. The items of I-QOL focus on three dimensions, namely social embarrassment, avoidance behaviors and psychosocial impacts, without physical mobility and self-care ability. Barthel Index is added to evaluate patients' activities of daily living, which is recognized as a valid and reliable outcome measurement for stroke survivors^[52].

One limitation of this pilot study is that we will be unable fail to prevent therapists and participants from knowing the group allocation because of the characteristics of moxibustion. To minimize the bias, acupuncturists will receive professional training and strict quality control. In order to homogenize the psychological effects, participants are informed that effects of the two moxibustion techniques are uncertain. The words 'placebo' or 'control' will be avoided. Similar strategies have been applied in previous trials^[62, 63]. Noncompliance of the control group is another limitation defeiency of this pilot trial and may lead to a high drop-out rate. Each participant will be provided with 150 RMB as financial compensation to improve compliance. We will solve this problem by providing participants with financial compensations and free moxibustion therapies after the completion of the entire trial.

This study is the major sub-project focusing on stroke recovery, which is sponsored and funded by the National Administration of Traditional Chinese Medicine of China. This protocol describes the first pilot randomized controlled trial evaluating the feasibility to conduct a research to assess the ~~efficacy curative effects~~ and safety of ginger-salt-indirect moxibustion on UUI after stroke. Results of this preliminary study will provide essential information for the design of subsequent large-scale trials. Further trials will focus on assessment of urodynamic parameters and evaluation of efficacy and safety of moxibustion on UUI after stroke.

Trial status

The trial is currently in the recruitment phase.

Author affiliations

¹Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China

²Research Center of Clinical Epidemiology Affiliated to Peking University Third Hospital, China

Contributors LPW and HLL conceived this study and prepared the initial protocol. LLW drafted the manuscript and participated in design of the study. GXS, YY, LZ, TZ participated in revising the protocol. LZ plans for the statistical analysis. LPW and HLL made amendments of the trial protocol. All authors read and approved the final manuscript.

Funding The trial is sponsored and funded by special project for the national clinical research bases construction of traditional Chinese medicine belonging to the State Administration of Traditional Chinese Medicine of the People's Republic of China, grant number: JD2X2012152.

Ethics approval Research ethics approval was attained from the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (ref: 2013BL-094).

Competing interests None.

Figure 1. Trial profile

Figure 2. Moxa cone moxibustion

Figure 3. Moxa box moxibustion

Figure 4. 72-hour frequency-volume chart

REFERENCES

1. Abrams P, Andersson K E, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn.* 2010; 29: 213-240.
2. Brittain K R, Peet S M, Potter J F, et al. Prevalence and management of urinary incontinence in stroke survivors. *Age Ageing.* 1999;28: 509-511.
3. Marinkovic S P, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. *J Urol.* 2001;165: 359-370.

4. Barrett J. Bladder and bowel problems after stroke. *Reviews in Clinical Gerontology*. 12: 253-267.
5. Williams M P, Srikanth V, Bird M, et al. Urinary symptoms and natural history of urinary continence after first-ever stroke--a longitudinal population-based study. *Age Ageing*. 2012; 41: 371-376.
6. Gelber D A, Good D C, Laven L J, et al. Causes of urinary incontinence after acute hemispheric stroke. *Stroke*. 1993;24: 378-382.
7. Santiago S K, Arianayagam M, Wang A, et al. Urinary incontinence-pathophysiology and management outline. *Aust Fam Physician*. 2008; 37: 106-110.
8. Manack A, Motsko S P, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. *Neurourol Urodyn*. 2011;30: 395-401.
9. Nakayama H, Jorgensen H S, Pedersen P M, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. *Stroke*. 1997;28: 58-62.
10. Anderson C S, Jamrozik K D, Broadhurst R J, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. *Stroke*. 1994;25: 1935-1944.
11. Patel M, Coshall C, Rudd A G, et al. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. *Stroke*. 2001; 32: 122-127.
12. Kolominsky-Rabas P L, Hilz M J, Neundoerfer B, et al. Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. *Neurourol Urodyn*. 2003; 22: 322-327.
13. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil*. 2005; 12: 66-76.
14. Gross J C. A comparison of the characteristics of incontinent and continent stroke patients in a rehabilitation program. *Rehabil Nurs*. 1998; 23: 132-140.
15. Hu T W, Wagner T H, Bentkover J D, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology*. 2004; 63: 461-465.
16. Levy R, Muller N. Urinary incontinence: economic burden and new choices in pharmaceutical treatment. *Adv Ther*. 2006; 23: 556-573.
17. Wyman J F, Burgio K L, Newman D K. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. *Int J Clin Pract*. 2009; 63: 1177-1191.
18. Godec C J. "Timed voiding"--a useful tool in the treatment of urinary incontinence. *Urology*. 1984; 23: 97-100.
19. DK N: Conservative therapy for incontinence. In: *Female Urology: a Practical Clinical Guide*. Edited by Goldman, HB VS. New York: Humana Press; 2007: 63-79.
20. Beetz R. Mild dehydration: a risk factor of urinary tract infection? *Eur J Clin Nutr*. 2003; 57: S52-S58.
21. DK N: Lifestyle interventions. In: *Pelvic Floor Disorders*. Edited by Bourcier AP ME, P A. Philadelphia: Elsevier Saunders; 2004: 269-276.
22. Koskimaki J, Hakama M, Huhtala H, et al. Association of smoking with lower urinary tract symptoms. *J Urol*. 1998; 159: 1580-1582.
23. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)*. 1991; 3: 161-170.
24. Richter H E, Creasman J M, Myers D L, et al. Urodynamic characterization of obese women with

- 1
2
3 urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by
4 Diet and Exercise (PRIDE) trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008; 19: 1653-1658.
- 5
6 25. Milne J L. Behavioral therapies for overactive bladder: making sense of the evidence. *J Wound*
7 *Ostomy Continence Nurs.* 2008; 35: 93-101, 102-103.
- 8
9 26. Burgio K L. Behavioral treatment options for urinary incontinence. *Gastroenterology.* 2004; 126:
10 S82-S89.
- 11
12 27. Burgio K L. Current perspectives on management of urgency using bladder and behavioral training.
13 *J Am Acad Nurse Pract.* 2004; 16: 4-7.
- 14
15 28. Burgio K L, Goode P S, Locher J L, et al. Behavioral training with and without biofeedback in the
16 treatment of urge incontinence in older women: a randomized controlled trial. *JAMA.* 2002; 288:
17 2293-2299.
- 18
19 29. Burgio K L, Locher J L, Goode P S, et al. Behavioral vs drug treatment for urge urinary
20 incontinence in older women: a randomized controlled trial. *JAMA.* 1998; 280: 1995-2000.
- 21
22 30. Wyman J F, Fantl J A, Mcclish D K, et al. Comparative efficacy of behavioral interventions in the
23 management of female urinary incontinence. Continence Program for Women Research Group.
24 *Am J Obstet Gynecol.* 1998; 179: 999-1007.
- 25
26 31. Mattiasson A, Blaakaer J, Hoyer K, et al. Simplified bladder training augments the effectiveness of
27 tolterodine in patients with an overactive bladder. *BJU Int.* 2003; 91: 54-60.
- 28
29 32. Brown JH LN: Muscarinic receptor agonists and antagonists. In: *Goodman & Gilman's The*
30 *Pharmacological Basis of Therapeutics.* Edited by Brunton L CBCB, 12th edn. New York:
31 McGraw-Hill;2011: 219-237.
- 32
33 33. Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder. *BJU Int.* 2007;
34 100: 987-1006.
- 35
36 34. Lam S, Hilas O. Pharmacologic management of overactive bladder. *Clin Interv Aging.* 2007; 2:
37 337-345.
- 38
39 35. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized
40 controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol.* 2008; 54: 740-763.
- 41
42 36. Chapple C R. Muscarinic receptor antagonists in the treatment of overactive bladder. *Urology.*
43 2000; 55: 33-46, 50.
- 44
45 37. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
46 bladder: a systematic review and meta-analysis. *Eur Urol.* 2005; 48: 5-26.
- 47
48 38. Chapple C R, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive
49 bladder: an update of a systematic review and meta-analysis. *Eur Urol.* 2008; 54: 543-562.
- 50
51 39. George A. Management of Urinary Incontinence. *P&T.* 2012; 6: 345-361.
- 52
53 40. Thomas L H, Cross S, Barrett J, et al. Treatment of urinary incontinence after stroke in adults.
54 *Cochrane Database Syst Rev.* 2008: D4462.
- 55
56 41. Thomas L H, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke
57 in adults. *Cochrane Database Syst Rev.* 2005;3: D4462.
- 58
59 42. Dong H ZX: An overview of traditional Chinese medicine. Traditional Medicine in Asia. In: *New*
60 *Delhi: World Health Organisation.* Edited by Chaudhary RR RU: Regional Office South -East
Asia; 2002: 17-30.
43. H. Qinfeng W H L J. Bibliometric analysis of diseases spectrum of moxibustion therapy. *Journal of*
Acupuncture and Tuina Science. 2012; 6: 334-342.
44. Deng H, Shen X. The Mechanism of Moxibustion: Ancient Theory and Modern Research. *Evid*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Based Complement Alternat Med.* 2013; 379291.
45. Liu H L, Wang L P. [Randomized controlled study on ginger-salt-partitioned moxibustion at shenque (CV 8) on urination disorders poststroke]. *Zhongguo Zhen Jiu.* 2006; 26: 621-624.
46. Sa J. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut Statist.* 2005: 287-291.
47. Cheng C W, Fu S F, Zhou Q H, et al. Extending the CONSORT Statement to moxibustion. *J Integr Med.* 2013; 11: 54-63.
48. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of days required to obtain reliable results. *Neurol Urodyn.* 2003; 22: 92-96.
49. Lucas M G, Bosch R J, Burkhard F C, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur Urol.* 2012; 62: 1130-1142.
50. Ku J H, Jeong I G, Lim D J, et al. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. *Neurol Urodyn.* 2004; 23: 331-335.
51. Wagner T H, Patrick D L, Bavendam T G, et al. Quality of life of persons with urinary incontinence: development of a new measure. *Urology.* 1996; 47: 67-71, 71-72.
52. Duffy L, Gajree S, Langhorne P, et al. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. *Stroke.* 2013; 44: 462-468.
53. Park J E, Lee S S, Lee M S, et al. Adverse events of moxibustion: a systematic review. *Complement Ther Med.* 2010; 18: 215-223.
54. Ernst E. Testing traditional cupping therapy. *J Pain.* 2009; 10: 555.
55. Yap T L, Cromwell D C, Emberton M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. *BJU Int.* 2007; 99: 9-16.
56. Brown J S, Mcnaughton K S, Wyman J F, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. *Urology.* 2003; 61: 802-809.
57. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, et al: The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. *Neurol Urodyn.* 2013; 22:1-5.
58. Bright E, Cotterill N, Drake M, et al: Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. *Eur Urol* 2014;66:294-300.
59. Groutz A, Blaivas J G, Chaikin D C, et al. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol.* 2000; 164: 698-701.
60. Tincello D G, Williams K S, Joshi M, et al. Urinary diaries: a comparison of data collected for three days versus seven days. *Obstet Gynecol.* 2007; 109: 277-280.
61. Avery K N, Bosch J L, Gotoh M, et al. Questionnaires to assess urinary and anal incontinence: review and recommendations. *J Urol.* 2007; 177: 39-49.
62. Linde K, Dincer F. How informed is consent in sham-controlled trials of acupuncture? *J Altern Complement Med.* 2004; 10: 379-385.
63. Shi G X, Han L L, Liu L Y, et al. Acupuncture at local and distant points for tinnitus: study protocol for a randomized controlled trial. *Trials.* 2012; 13: 224.




Figure1. Trail flowchart
32x31mm (300 x 300 DPI)



Figure 2. Moxa cone moxibustion
115x77mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 3. Moxa box moxibustion
92x61mm (600 x 600 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

72-hour frequency-volume chart

Date	Time (a.m/p.m)	Volume voided (ml)	urinary incontinence (tick in the blank)	notes

Figure 4. 72-hour frequency-volume chart
100x53mm (300 x 300 DPI)

review only